University of Kentucky

UKnowledge
Biomedical Engineering Faculty Patents

Biomedical Engineering

2-20-2018

Bilayered Calcium Sulfate/Calcium Phosphate Space-Making
Composites with Multiple Drug Delivery Capabilities
David A. Puleo
University of Kentucky, dave.puleo@uky.edu

Bryan R. Orellana
University of Kentucky, bryan.orellana@gmail.com

Mike McQuinn
University of Kentucky, mike.mcquinn@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/cbme_patents
Part of the Biomedical Engineering and Bioengineering Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Puleo, David A.; Orellana, Bryan R.; and McQuinn, Mike, "Bilayered Calcium Sulfate/Calcium Phosphate
Space-Making Composites with Multiple Drug Delivery Capabilities" (2018). Biomedical Engineering
Faculty Patents. 15.
https://uknowledge.uky.edu/cbme_patents/15

This Patent is brought to you for free and open access by the Biomedical Engineering at UKnowledge. It has been
accepted for inclusion in Biomedical Engineering Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

I IIIII I IIIIII Il llll lllll lllll lll l lllll lllll l lll lll l 111111111111111111
US009895354B2

c12)

United States Patent
Puleo et al.

(54) BILAYERED CALCIUM SULFATE/CALCIUM
PHOSPHATE SPACE-MAKING COMPOSITES
WITH MULTIPLE DRUG DELIVERY
CAPABILITIES
(71) Applicant: University of Kentucky Research
Foundation, Lexington, KY (US)
(72)

Inventors: David Puleo, Lexington, KY (US);
Bryan Orellana, Lexington, KY (US);
Mike McQuinn, Lexington, KY (US)

(73)

Assignee: UNIVERSITY OF KENTUCKY
RESEARCH FOUNDATION,
Lexington, KY (US)

( *)

Notice:

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by O days.

(21)

Appl. No.: 14/678,457

(22) Filed:

Apr. 3, 2015

(65)

Prior Publication Data
US 2015/0283089 Al

Oct. 8, 2015

Related U.S. Application Data
(60)

Provisional application No. 61/975,133, filed on Apr.
4, 2014.

(51)

Int. Cl.
A61K 9/14
(2006.01)
A61K 31/4174
(2006.01)
A61K 31/366
(2006.01)
A61L 27154
(2006.01)
A61K 9/20
(2006.01)
A61K 9/24
(2006.01)
A61L 27146
(2006.01)
A61L 27152
(2006.01)
A61K 31/4164
(2006.01)
(52) U.S. Cl.
CPC .......... A61K 31/4174 (2013.01); A61K 9/146
(2013.01); A61K 9/209 (2013.01); A61K
9/2009 (2013.01); A61K 9/2086 (2013.01);
A61K 9/2095 (2013.01); A61K 31/366
(2013.01); A61K 31/4164 (2013.01); A61L
27146 (2013.01); A61L 27152 (2013.01); A61L
27154 (2013.01)
(58) Field of Classification Search
CPC .. A61K 9/5015; A61K 9/145; A61K 31/4174;
A61K 31/366
USPC .......................... 424/484, 497; 514/398, 460
See application file for complete search history.
(56)

References Cited
U.S. PATENT DOCUMENTS
5,462,722 A
5,776,193 A

10/1995 Liu et al.
7/1998 Kwan et al.

(IO)
(45)

Patent No.:
US 9,895,354 B2
Date of Patent:
Feb.20,2018

6,030,636
6,311,690
6,764,517
6,998,137
7,241,316
7,575,780
7,758,882
7,833,278
7,863,352
7,892,291
8,012,501
8,419,802
8,496,955
8,586,074
8,603,183
2003/0045924

A
Bl
B2
B2
B2
B2
B2
B2
B2
B2
B2
B2
B2
B2
B2
Al*

2/2000
11/2001
7/2004
2/2006
7/2007
8/2009
7/2010
11/2010
1/2011
2/2011
9/2011
4/2013
7/2013
11/2013
12/2013
3/2003

2004/0002770
2007/0190102
2007/0248675
2007/0255422
2008/0233165
2008/0292839

Al
1/2004
Al
8/2007
Al 10/2007
Al 11/2007
Al
9/2008
Al* 11/2008

2010/0185200
2011/0060413
2011/0208305
2012/0053692
2012/0095518
2012/0136441
2012/0189683
2012/0207839
2012/0310366

Al
7/2010
Al
3/2011
Al
8/2011
Al
3/2012
Al
4/2012
Al
5/2012
Al
7/2012
Al
8/2012
Al* 12/2012

2013/0171221 Al
7/2013
2013/0273135 Al 10/2013
2013/0297038 Al* 11/2013
2013/0345825 Al

12/2013

Randolph et al.
Jefferies
Yamamoto et al.
Shih et al.
Evans et al.
Alexander et al.
Roeder et al.
Evans et al.
Ricci et al.
Evans et al.
Kerr et al.
Evans et al.
Cooper
Mamidwar et al.
Ding
Datta ........................ A61F 2/88
623/1.15
King et al.
Luo
Tae et al.
Wei et al.
Alexander et al.
Wei ......................... A61L 27/46
428/113
Dricot
Kasuga et al.
Malinin et al.
Voor et al.
Ju et al.
Yang et al.
Yang et al.
Liu et al.
Li .......................... A61K 31/22
623/23.57
Deng et al.
Brooks et al.
McKay ..................... A61F 2/28
623/23.57
Butler

OTHER PUBLICATIONS
Chou et al.; Title: Controlled Release of Simvastatin from
Biomimetic 13-TCP Drug Delivery System; PLOS ONE. Jan. 2013,
vol. 8 Issue 1, Special section p. 1-6.*
Greenwald et al, title: Bone-graft substitutes: facts, fictions &
applications, American academy of orthopedic surgeons, 73rd
Annual Meeting, Mar. 22-26, 2006.*
Author: Orellana et al.; Title: Bioerodible calcium sulfate/poly((i3amino ester) hydrogel composites, J Mech Behav Biomed Mater.
Oct. 2013;26:43-53; Epub May 31, 2013.*

* cited by examiner
Primary Examiner - Yanzhi Zhang
(74) Attorney, Agent, or Firm - King & Schickli PLLC
(57)

ABSTRACT

The present invention provides for bilayered composites that
provide for sustained drug delivery and support to recover
ing tissue(s) and areas surrounding, such as with bone tissue.
The two layers degrade at separate rates, thereby providing
sustained mechanical support and tailored drug delivery.
20 Claims, 19 Drawing Sheets
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BILAYERED CALCIUM SULFATE/CALCIUM
PHOSPHATE SPACE-MAKING COMPOSITES
WITH MULTIPLE DRUG DELIVERY
CAPABILITIES
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Patent
Application 61/975,133, filed 4 Apr. 2014, which is hereby
incorporated by reference in its entirety.
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GOV ERNMENT INTEREST
This invention was made with Govermnent support from
grants NIH DE019645 and EPS-0814194 awarded by the
National Institutes for Health and the National Science
Foundation, respectively. The Govermnent may have certain
rights in the invention.
TECHNICAL FIELD
The present invention relates generally to methods of
improving bone regeneration or augmentation through the
introduction of bilayered composites comprising an outer
shell and an inner core, wherein the two layers degrade or
erode at different rates in situ, thereby allowing for mechanical support to tissues while improving administration of
therapeutic compounds dispersed within one or both of the
layers.
BACKGROUND
A traumatic event to the bone, such as that seen with
surgical procedures, can require many varied therapies to
improve recovery and healing. Often it is contemplated that
providing mechanical support in conjunction with delivering
therapeutic compounds at the surgical site can aid in improv
ing the recovery process. However, the differing rates of
absorption and metabolism can make effective delivery very
complicated. The capacity to quickly regenerate or augment
bone lost as a result of resorption and trauma is crucial to
restoring proper function and aesthetics. In addition to
existing bone grafts, both autologous and allogeneic, a
variety of bone graft substitutes are being developed (Ilan D.
I, Ladd A. L. (2004) Bone graft substitutes, Operative
Techniques in Plastic and Reconstructive Surgery, 9.4, 151160).
A common procedure to treat osseous defects is bone
grafting which takes tissue from a donor site that is trans
planted to a defective region. For instance, in dentistry, this
procedure is used in conjugation with guided bone regen
eration (GBR) for regions in the mandible where bone has
been resorbed or deformed due to the loss of teeth, peri
odontal disease or trauma to the jaw. GBR is a procedure
which implants a barrier membrane over donated bone
material to prevent infiltration of epithelium and connective
tissue which may disrupt bone formation (Simian, M.,
Fontana, F., Rasperini, G., Maiorana, C., 2007. Vertical ridge
augmentation by expanded-polytetrafluoroethylene mem
brane and a combination of intraoral autogenous bonegraft
and deproteinized anorganic bovine bone (Bio Oss). Clinical
Oral Implants Research 18, 620-629). Depending on the
barrier material, there can be a tendency to collapse, which
will require bone grafting to provide a biodegradable and
stable support structure as osteogenesis occurs (Hitti, R. A.,
Kerns, D. G., 2011. Guided bone regeneration in the oral
cavity: a review. Open Pathology Journal 5, 33-45). How-
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20

2

ever, these procedures also may require a second surgery to
remove non-biodegradable barrier membranes, and bone
grafting may cause morbidity in the donor site (Chiapasco,
M., Zaniboni, M., Rimondini, L., 2007. Autogenous onlay
bone grafts vs. alveolar distraction osteogenesis for the
correction of vertically deficient edentulous ridges: a 2-4year prospective study on humans. Clinical Oral Implants
Research 18, 432-440; Guarnieri, R., Grassi, R., Ripari, M.,
Pecora, G., 2006. Maxillary sinus augmentation using
granular calcium sulfate (surgiplaster sinus): radiographic
and histologic study at 2 years. International Journal of
Periodontics and Restorative Dentistry 26, 79-85; Triplett,
R. G., Schow, S. R., 1996. Autologous bone grafts and
endosseous implants: Complementary techniques. Journal
of Oral and Maxillofacial Surgery 54, 486-494). A strong
biocompatible material that can effectively promote osteo
genesis while acting as an effective barrier and/or support
thus preventing disruptive tissue from infiltrating would be
an effective alternative for the procedure. Release of bioac
tive agents and/or the combination of materials to create a
stable augmenting platform could be a suitable substitute to
the existing standard autografts.
SUMMARY OF THE INV ENTION
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The present invention provides for a bilayered composite
to provide mechanical support, as well as to provide local
ized drug delivery comprising an outer shell layer and an
inner core layer, wherein one layer degrades in situ within a
subject at a rate faster than the other layer. The outer shell
layer may degrade faster than the inner core layer, or the
inner core layer may degrade faster than the outer shell layer.
One layer layer may comprise a material selected from the
group consisting of dicalcium phosphate dihydrate (DCPD),
hydroxyapatite, calcium-deficient hydroxyapatite, carbon
ate-substituted hydroxyapatite, and calcium polyphosphate.
The other layer may comprise a material selected from the
group consisting of calcium sulfate (CS), (3-tricalcium
phosphate, amorphous calcium phosphate, monetite, and
tetracalcium phosphate.
In certain embodiments, one layer comprises calcium
sulfate and the other layer comprises calcium phosphate.
The calcium phosphate may be dicalcium phosphate dehy
drate.
In certain embodiments, at least one layer further may
comprise a pharmaceutical agent selected from the group
consisting of: simvastatin, lovastatin, rosuvastatin, SVAK12, bone morphogenetic proteins, parathyroid hormone
(1-34), metronidazole, doxycycline, vancomycin, gentamy
cin, ciprofloxacin, ketoprofen, celecoxib, diclofenac,
meloxicam or combinations thereof. In other embodiments,
both layers further comprise a pharmaceutical agent.
Optionally, the pharmaceutical agent may be preloaded in a
degradable matrix or a hydrogel.
The present invention also provides methods of providing
tissue support to a subject in need thereof, comprising
administering the bilayered composite to tissue of a subject.
The tissue may be osseous tissue. The subject may be an
animal, such as a vertebrate. The subject may be a fish,
mammal, amphibian, reptile or bird. The subject may be a
human. The methods may further comprise preloading at
least one layer with a pharmaceutical agent. Optionally, the
pharmaceutical agent is in a degradable matrix or hydrogel
within the layer.
BRIEF DESCRIPTION OF THE DRAWINGS
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FIG. 1 shows a schematic depicting the process of form
ing a bilayered CS composite. From left to right: core

US 9,895,354 B2
4

3

formation; insertion of core into shell mold; final composite
showing core encased within a CS shell. Images are to scale.
FIG. 2 shows cumulative release of metronidazole from
150-250 µm PLGA particles. Data are mean±standard devia
tion (n=3).
FIG. 3 shows representative microCT images of
CS/PLGA composites: raw X-ray slices and cross-sections
of 3D reconstructions. Closed arrows mark bubbles, and
open arrows with circles indicate PLGA particles. Scale bars
denote 1 mm.
FIG. 4 shows volume percentage of voids/particles in
CS/PLGA composites determined by microCT. Data are
mean±standard deviation (n=5). Symbols (*) indicates sig
nificant differences (p<0.001).
FIG. 5 shows mass loss profiles for bilayered blank CS
and composites with 1 and 10 wt % PLGA loaded into the
shells. Data are mean±standard deviation (n=3).
FIG. 6 shows mechanical properties of CS/PLGA com
posites with directly loaded simvastatin: A) ultimate com
pressive strength and B) compressive modulus. Data are
mean±standard deviation (n=5). Symbols indicate signifi
cant differences: p<0.001 (*), p<0.01 (#), and p<0.05 (ll).
FIG. 7 shows cumulative release of simvastatin from
bilayered samples having different shell to core volume
ratios: (A) 85:15; (B) 75:25; and (C) 50:50. Data are
mean±standard deviation (n=5).
FIG. 8 shows cumulative release of simvastatin from
bilayered samples incubated below sink conditions. The
samples tested had a 50:50 shell to core volume ratio. Data
are mean±standard deviation (n=5).
FIG. 9 shows cumulative release of simvastatin and
metronidazole from bilayered composites. Normalized pro
files of directly loaded simvastatin and metronidazole loaded
into PLGA particles released from composites with (A) 1 wt
% and (B) 10 wt% PLGA particles loaded in shells. Data are
mean±standard deviation (n=5).
FIG. 10 shows a schematic depicting the packing of the
DCPM core and injection of CS shell around the core. The
bottom, red portion, of each mold is removable allowing for
the punching out of the samples. Final adjustments are made
to the exposed portion of the DCPM core by sanding it flush
to the shell.
FIG. 11 shows microCT reconstructions of microarchi
tectural changes for A.) CS in shell, DCPD in Core samples,
and B.) DCPD in Shell, CS in Core samples.
FIG. 12 shows cumulative release of simvastatin from CS
(top) and DCPD (bottom) samples at 1 wt % Data is
mean±standard error of mean (SEM) (n=5).
FIG. 13 shows cumulative releases of simvastatin from
DCPD samples at 1 wt %, 2 wt %, and 4.8 wt %. Data is
mean±SEM (n= 5).
FIG. 14 shows cumulative releases of simvastatin from
CSs/CPs, CPs/CSs, CPs/CS, and CS/CPs. Simvastatin load
ings are denoted by the lowercase s. 2 wt % is loaded in
DCPD layers and 1 wt % in CS layer.
FIG. 15 shows compressive elastic modulus and ultimate
compressive stress of non-layered and bilayered CS and
DCPD implants at different simvastatin loadings in non
layered samples. Data is mean±SEM (n=8-10).
FIG. 16 shows percentage of initial mass remaining from
DCPD samples at every 8 days over a period of 128 days.
Data are mean±SEM (n= 3).
FIG. 17 shows microCT cross-sections of DCPD samples
during erosion in PBS.
FIG. 18 shows compression testing results displaying the
ultimate compressive stress (UCS, left) and the compressive
elastic modulus (M, right).

FIG. 19 shows representative mass loss (top) and pH
(bottom) during destructive degradation testing.
DESCRIPTION
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The present invention provides for a bilayered composite
to assist in bone augmentation, such as rebuilding and
healing at the site of injury or surgical repair to bone or
osseous tissue, such as that seen with dental or orthopedic
surgeries. The bilayered composites of the present invention
comprise an outer shell layer and an inner core layer. Either
layer may be loaded or incorporated with a therapeutic
compound, either both with the same or with different
compounds. The two layers are comprised of biomaterials
that degrade or erode at different rates once placed in situ
within a subject. The bilayered composites, in addition to
delivering therapeutic compounds, further provide structural
protection, such as a "tenting" of surrounding soft tissue to
create a regeneration chamber for bone, thus removing need
for harvesting tissue for grafts. The following describe
background of the present invention: Oreliana, B. R.,
Thomas, M. V., Hilt, J. Z., and Puleo, D. A. (2013).
Bioerodible calcium sulfate hemihydrate/poly(�-amino
ester) hydrogel composites, J. Mech. Behav. Biomed. Mater.
26:43-53; Oreliana, B. R. and Puleo, D. A. (2014). Tailored
sequential drug release from bilayered calcium sulfate com
posites, Mater Sci Eng C Mater Biol Appl. 43:243-52;
Oreliana, B. R., Hilt, J. Z., and Puleo, D. A. (2015). Drug
release from calcium sulfate-based composites, J. Biomed
Mater Res. Part B 2015 103(1): 135-42; Oreliana, B., Hawk
ins, A. M., Thomas, M. V., Hilt, J. Z., and Puleo, D. A.
(2010). Calcium sulfate/hydrogel space-making composites
for bone augmentation. Presented at the 2010 Annual Meet
ing of the Society For Biomaterials, April 21-24, Seattle,
Wash.; Oreliana, B. R, Thomas, M. V., Hilt, J. Z., and Puleo,
D. A. (2011). Drug delivery from calcium sulfate/hydrogel
space-making composites. Presented at the 2011 Annual
Meeting of the Society For Biomaterials, April 13-16,
Orlando, Fla.; Oreliana, B. R., Thomas, M. V., Hilt, J. Z., and
Puleo, D. A. (2012). Drug delivery from space-Making
calcium sulfate/poly(�-amino ester) hydrogel composites.
Presented at the AADR Annual Meeting, March 21-24,
Tampa, Fla.; Oreliana, B. R., Thomas, M. V., Hilt, J. Z., and
Puleo, D. A. (2013). Bilayered calcium sulfate space-making
composites with multiple drug delivery capabilities. Pre
sented at the 2013 Annual Meeting of the Society For
Biomaterials, April 10-13, Boston, Mass.; Oreliana, B. R.,
McQuinn, M. W., and Puleo, D. A. (2014). Tailored prop
erties of bilayered calcium sulfate and calcium phosphate
bone graft substitutes. Presented at the 2014 Annual Meeting
of the Society For Biomaterials, April 16-19, Denver, Colo.;
McQuinn, M. W., Oreliana, B. R., and Puleo, D. A. (2014).
Bilayered calcium phosphate/calcium sulfate bone graft
substitutes. Presented at the 2014 Annual Meeting of the
American Association of Oral and Maxillofacial Surgeons,
September 8-13, Honolulu, Hi.; Gu, Y., Oreliana, B. R., and
Puleo, D. A. (2015). Simvastatin-releasing calcium sulfate
and calcium phosphate bioceramics. Presented at the 2015
Annual Meeting of the Society For Biomaterials, April
15-18, Charlotte, N.C.
Because space maintenance and stimulation of osteogen
esis is important for many dental, craniofacial, and ortho
pedic procedures, the implanted bilayered composites of the
present invention can be useful in many applications requiring bone grafting/bone graft substitutes. These include ridge
augmentation for placement of dental implants, ridge pres
ervation following tooth extraction, reconstruction of cavi-
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tary bone defects, regeneration in segmental bone loss, and
enhancement of interbody spinal fusion.
The bilayered composite system of the present invention
is amenable to formulation with varied biomaterials.
According to the present invention, one of the selected
biomaterials should be proceed at a slower eroding/degrad
ing/dissolving rate than the other. Those skilled in the art
will appreciate that different benefits may be achieved when
the order of the layers is varied. For example, placement of
the more rapid degrading biomaterial as the outer shell,
allows for faster rates of therapeutic delivery of compounds
contained in the outer layer, as well as a faster access to the
slower degrading core and any therapeutic compounds con
tained therein. Conversely, placement of the slower degrad
ing biomaterial as the outer core allows for reduced rates of
release of therapeutic compounds from this layer, as well as
a prolonged time of access to the core, as well as any
therapeutics contained therein.
As set forth in the working examples, dicalcium phos
phate dihydrate (DCPD or brushite, a form of calcium
phosphate, CP) provides for a slower degrading biomaterial
and calcium sulfate (CS) is a faster degrading biomaterial.
Other possible biomaterials include, but are not limited, to
the following:
Slower degrading: hydroxyapatite, calcium-deficient
hydroxyapatite, carbonate-substituted hydroxyapatite,
and calcium polyphosphate
Faster degrading: �-tricalcium phosphate, amorphous cal
cium phosphate, monetite, and tetracalcium phosphate
Further, as set forth in the working examples, metronidazole and simvastatin can be used as antimicrobial and
osteogenic agents that are impregnated or deposited into the
layers of the bilayered composite. Those skilled in the art
will appreciate that any therapeutic compound can be con
sidered, taking into account the respective solvency once in
situ, as well as how a selected agent may align/interact with
a potential biomaterial that formulates the particular layer.
Particular classes of therapeutic compound are worth con
sidering given the purpose of assisting in bone augmenta
tion. These include, but are not limited, to the following:
Antimicrobial agents-such as: metronidazole, doxycy
cline, vancomycin, gentamycin, and ciprofloxacin
Osteogenic agents-such as: simvastatin, lovastatin, rosu
vastatin, SVAK-12, bone morphogenetic proteins, and
parathyroid hormone (1-34)
Anti-inflammatory agents-such as: ketoprofen, celecoxib, diclofenac, and meloxicam
Those skilled in the art will appreciate that the therapeutic
agents incorporated within each layer may be further incased
in an additional biomaterial, such as a hydrogel or degradable matrix, to further affect the release. Examples include,
but are not limited to poly (lactic-co-glycolic) acid (PLGA),
poly(�-amino ester) (PBAE), cellulose acetate phthalate and
phronic F-127.
The tailorable bilayered composites may function as bone
graft substitutes or part thereof and provide the ability once
in situ to sequentially release multiple therapeutic agents. As
set forth in the working examples herein, microcomputed
tomography (MicroCT) images exemplify the overall lay
ered geometry as well as uniform distribution of particles
within the bilayered composites.
Those skilled in the art will appreciate that the portion
each layer contributes to the overall composition can alter
the activity and function when in situ. For example, the
working examples provide a demonstration of release of
simvastatin within a CS layer. The data generated from
sustained release of simvastatin directly loaded into CS
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demonstrate that changing the shell to core volume ratio
dictates the duration of drug release from each layer.
By introducing a tunable layered geometry capable of
releasing multiple drugs, the bilayered composites of the
present invention provide bone graft substitutes that can be
tailored in order to help streamline multiple steps needed to
regenerate tissue in infected defects. As also demonstrated in
the working examples, when loaded together in the shell or
in separate layers, sequential release of two therapeutic
agents is achieved. Qualitative assessment of the morphol
ogy of bilayered composites showed good distribution of
therapeutic carrying degradable matrix, such as PLGA,
microparticles (without or loaded with a therapeutic agent)
embedded in at least one layer of the bilayer composite
between 1 and 10 wt %. Those skilled in the art will
appreciate that higher content can also be utilized, particu
larly in instances where the mechanical support is of reduced
concern, such as with non-load bearing sites. Although the
embedded particles were distributed throughout the matrix,
they did not appear to be interconnected, which otherwise
would have allowed for fluid to seep into the composite.
During erosion, closed pockets with drug-loaded particles
near the surface were exposed, thereby releasing the poly
mer particles. The introduction of a bilayered geometry
affected properties compared to solid samples, with a reduc
tion in the strength and elastic modulus. The loading of
therapeutic compounds directly into the shell, core, or both
layers did not significantly affect the strength of the bilay
ered composites. The layered geometry used from the
examples described herein demonstrate a unique platform
for achieving customizable sequential release of therapeutic
agents. Loading of drug carrying microparticles into the
matrix allows for further tailoring of drug release.
The release of therapeutic compounds and the carriers
thereof can be tailored depending on the layer in which the
therapeutics are loaded. For example, as set forth in the
examples, simvastatin delivery can be tailored depending on
whether it was the shell only, core only, or both.
To further adjust the duration or even the delay of drug
release from either the shell or core, the shell to core volume
ratio can be altered. For example, the findings for samples
with metronidazole within PLGA particles and with simv
astatin directly loaded into a shell demonstrated sequential
release: polymeric particles loaded with metronidazole and
embedded into the shell were exposed as the shell experi
enced surface erosion, and a sustained release of the drug
occurred as the PLGA particles subsequently degraded. To
further enhance the process of fighting infection and then
regenerating lost tissue, release of an anti-bacterial agent
from the graft starting at the time of implantation can be
beneficial to help reduce the overall healing time. The
release of a therapeutic, as seen with simvastatin in the
examples, is, therefore, governed by the surface erosion
characteristics, which have demonstrated to be linear, allow
ing for a near constant rate of release of simvastatin. The
apparent differences in release kinetics between the two
drugs and their means of loading allowed for enough sepa
ration for all the metronidazole to be released approximately
4 days sooner than simvastatin. Conversely, when simvas
tatin was loaded into only the core and PLGA particles
loaded with metronidazole remained in the shell, there was
a much greater lapse in time for a fully separated sequential
release to occur. Instances such as this can mimic the clinical
sequence of events for treating infection and subsequently
restoring lost or damaged tissue. When metronidazole and
simvastatin were loaded together in the shell or in separate
layers, temporal separation of the two drugs was achieved.
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The ability of the present invention to provide tailored
release of therapeutic agents as well as a sequential release
of different drugs, may be utilized in many scenarios, such
as a bone graft substitute for treating infected bony defects,
e.g., periodontal pockets. Changing the shell to core volume
ratio dictates the duration of drug release from each layer.
With the bilayered composites of the present invention,
the ratio of shell to core may vary according to the desired
outcome. The percent of shell to the total composite may be
5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, or 95%. Conversely, the percent of the core to the
total composite may be 5, 10, 15, 20, 25, 30, 35, 40, 45, 50,
55, 6� 65, 7� 75, 8� 85, 9� or 95%.
The therapeutic compounds loaded into the layers of the
composite may comprise any known pharmacologic agent or
any combination thereof. Therapeutic agents may be
encased or protected prior to loading within either layer of
the shell, such as with degradable matrices like PLGA.
Examples of therapeutic compounds that may be beneficial
to osseous tissue, such as bone and/or dental areas, receiving
the bilayered composites include: proteins/growth factors,
such as bone morphogenetic proteins (BMPs) 2, 4, 7, and 9;
statin drugs, such as simvastatin, lovastatin, fluvastatin, and
mevastatin; antibiotics, such as metronidazole, doxycycline,
gentamicin, and vancomycin; and anti-inflammatory agents,
such as ketoprofen, naproxen, and celecoxib.
With regard to oral surgeries, in testing the bilayered
composites, it was noted that although the compressive
properties decreased with the introduction of a layered
geometry, the resulting strengths seen with faster degrading
materials, such as calcium sulfate, in the bilayered compos
ites remained either similar to or stronger than the strength
of trabecular bone in the mandible and the combination of
the faster/slower degrading materials, such as calcium sul
fate/calcium phosphate samples, were even stronger still.
The present invention provides for bilayered composites
in a variety of final shapes. Preformed scaffolds can be
designed to allow fabrication of a variety of shapes. The
bilayered geometry allows for sequential release of multiple
drugs. Incorporated biomaterial of differing degradation
rates, such as CS and DCPD, into separate layers allows for
customizable erosion. For example, structures can exhibit
fast initial erosion of a CS shell while maintaining the DCPD
core and vice versa. Examples of microCT reconstructions
of dissolution trends are seen in FIG. 8.
The erosion pattern of the layered materials within the
bilayered composites allows for erosion tuning and customi
zable drug release that further assist in functioning as a bone
graft substitute. Slower degrading biomaterials, such as
DCPD, have demonstrated to be a more durable ceramic as
compared to fast degrading materials, such as CS, lasting
well over 180 days in release studies. For example, DCPD
samples sustained much larger compressive forces and
released at much slower yet steady rates in lower loadings.
The bulk degradation property of CP may be beneficial for
bone augmentation by allowing for cell infiltration and
increasing surface area for growth. Bilayered composites are
able to degrade and permit more space for bone growth than
non-layered samples of slower degrading material, such as
DCPD, while also maintaining a longer lasting support
structure, unlike faster degrading materials like CS.
Bilayered composites of the present invention can further
act as 'tenting' barriers to prevent or hinder soft tissue
infiltration, while allowing a well-tailored delivery of a
variety of treatment specific drugs directly loaded in the
material of a particular layer and/or embedded in biodegrad
able hydrogel particles. The release of bioactive agents
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and/or the combination of materials to create a stable
augmenting platform suitable as a substitute to the existing
standard autografts.
The bilayered composites of the present invention provide
for a composite that retains the benefits from the properties
of the biomaterial of each layer, with the addition of the
other layer overcoming any deficiencies. For example, as set
forth in the working examples, release of simvastatin
directly loaded into a "fast" degrading material implant,
calcium sulfate (CS), and a "slow" degrading material
implant, calcium phosphate (CP) (such as DCPD), demonstrated release rates of approximately 59 and 7 µg/day for CS
and CP, respectively. Mechanical testing showed CP to have
significantly (p<0.05) greater compressive strength (FIG. 15
and modulus than did CS. There were no significant differ
ences between CP of different simvastatin loadings. CP
eroded much more slowly than CS when incubated in
phosphate-buffered saline; CS was gone within 28 days,
while CP lasted more than 180 days. Loading did not affect
erosion. MicroCT scans showed that CP developed a porous
internal structure as it eroded (FIG. 17). However, in combining the slow dissolving properties of DCPD with CS in
a bilayered composite, a 'middle ground' is established
where sufficient scaffolding is maintained as CS dissolves
and cell infiltration occurs in the slower dissolving DCPD.
Release of simvastatin from CS samples occurred at a much
higher rate than DCPD samples, as expected from CS's
faster dissolution rate. Release rates were approximately 247
and 29 µg/day for CS-1 and CP-1, respectively. Increasing
the amount of simvastatin added to DCPD resulted in a
loading-dependent increase in release rate (i.e., 45 and 105
µg/day for 2 and 4.8 wt % simvastain loadings, respec
tively). Mechanical testing showed DCPD to all have sig
nificantly (p<0.05) greater ultimate compressive strength
and compressive modulus than did CS (FIG. 15). Addition
ally the strength and modulus of both bilayered samples
were significantly lower (p<0.01) than that of DCPD blanks.
The compressive mechanical properties of both bilayered
samples were comparable (p>0.05) to that of CS blanks.
There was also no significant difference found between the
compressive mechanical properties of CS/CP bilayering
compared to CP/CS bilayering. MicroCT scans also showed
qualitatively that DCPD developed a porous internal struc
ture as it eroded.
According to the present invention, higher loadings
should be preferred over lower loadings in order to achieve
a higher average release rate, while lower loadings are
preferred over higher loadings in order to achieve a steadier
release rate. Due to rapid dissolution, faster degrading
material as the shell layering has a higher release rate in the
first weeks of its dissolution. Additionally, such samples
result in greater mass loss since more surface area is
exposed, leaving behind the slower degrading core. This is
beneficial for providing longer-lasting scaffolding for
implantations while also allowing room for sufficient bone
growth as the outer shell layer dissolves.
Degradation of the implants can be slowed by selecting a
slower degrading material as an outer shell and selecting the
faster degrading material to compromise the inner core. As
described herein, with the slower degrading DCPD and
faster degrading CS, DCPDs/CS and CS/DCPDs formula
tions had a slower yet more linear release rate compared to
other bilayered formulations. DCPD shells release at a
higher rate by occupying more volume compared to DCPD
cores. The formation of an empty core as slow degrading
shell samples dissolve can also be beneficial for providing
greater mechanical strength than a using a slow degrading
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core while also allowing for bone growth to occur at the
center of the shell. The quality for both fast and slow
degrading materials to retain their mechanical properties at
the loadings tested provides for more options in controlled
drug release which is important for regions of bone defect
where healing is slower and requires increased drug loadings
to compensate. The mechanical properties observed in the
examples were also found to be higher than those of trabe
cular bone in the mandibles (96.2 MPa compressive modu
lus; 3.9 MPa ultimate compressive strength) (Misch C E, Qu
Z, Bidez M W. Mechanical properties of trabecular bone in
the human mandible: Implications for dental implant treat
ment planning and surgical placement. J Oral Maxi! Surg.
1999; 57:700-6; McQuinn, M. (2014, September). Bilayered
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Poster presented at the 96'h Annual Scientific Sessions &
Exhibition, Honolulu, Hi.). Accordingly, while the bilayered
composites may not be as stiff as non-layered samples, they
can carry the same load before failure. A redeeming quality
is that the inclusion of slower degrading materials allows for
an adequate support structure in implantation sites much
longer due to its slower dissolution. The structure of slower
degrading materials, such as DCPD, allows for infiltration of
cells such as osteoblasts as it degrades while osteogenic
activities can promoted by the local release of a therapeutics
(seen with simvastatin in the examples). MicroCT scans of
such embodiments showed slight surface imperfections in
DCPD samples even before degradation testing began.
These surface imperfections were found to be as wide as 100
µm in diameter which is sufficient to permit infiltration of
osteoblasts (20-30 µm). The much slower degradation rate is
also beneficial for maintaining a slow consistent release over
a sustained period time as observed in the release study.
These issues can be addressed by combining the two ceramics using the bilayered composites, thereby providing a
longer lasting support structure (e.g., DCPD) while also
permitting sufficient bone growth to occur within the core as
the faster degrading material (e.g., CS) is dissolved. Further,
after bone ingrowth has occurred within the core of the
slower degrading shell, mechanical properties can expect to
see a boost due to the presence of both bone and the shell.
Additionally, cell infiltration and resorption can occur on
both sides of the shell, thereby allowing for better integra
tion of bone and effectively reducing the degradation time.
Additionally, the osteogenic activity can be enhanced by the
steady and predictable release of therapeutics (e.g., simvas
tatin) from the implanted composite, all without compro
mising the initial mechanical strength of the commonly used
biomaterial CS.
The present invention provides for methods of using the
bilayered composites. The methods comprise administering
to the osseous tissue of a subject the bilayered composites as
described herein. The subject can be a vertebrate animal,
such as a bird, reptile, amphibian, fish or mammal. The
subject may be a human. The osseous tissue may comprise
bone or periodontal tissue. The bilayered composite may be
applied directly to the tissue, such as through implantation
during surgery or may be applied less invasively, such as
through injection.
Once deposited, the bilayered composite remains in situ
with the subject. As described herein, the bilayered com
posite may release one or more pharmaceutical agents
within the subject. Further, as also described herein, the
bilayered composite provides structural support to the tissue,
as well as preventing or hindering surrounding soft tissue
from migrating to the osseous tissue. As described herein,
the degradable nature of both layers of the bilayered com-
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EXAMPLES
Example 1
Bilayered Calcium Sulfate Composites
Metronidazole-Loaded PLGA Particles
Poly(lactic-co-glycolic acid) (Durect Corp., Birmingham,
Ala.; 50:50; inherent viscosity: 0.55-0.75 dL/g; carboxylate
end group) particles loaded with metronidazole (Sigma
Aldrich, St. Louis, Mo.) were created by film-casting and
hand-grinding. Initially, 25 mg of metronidazole were com
bined with 200 mg of PLGA and dissolved in 1 mL of
dimethyl sulfoxide (DMSO; an FDA Q3C Class 3 solvent).
The solution was poured into a circular Teflon mold, frozen
quickly at -80° C., and lyophilized to remove the DMSO.
The dried film was hand ground to obtain particle sizes
between 150-250 µm. A small amount of CS was used to
prevent the polymer from sticking during grinding. The
particles were washed with ethanol to remove residual CS
powder on the surface of the polymer. Ethanol was chosen
for washing to prevent drug loss because the low solubility
of metronidazole in this solvent. Washed particles were
vacuum-filtered, rapidly air-dried, and stored at -20° C. until
used.
A short-term study of metronidazole-loaded micropar
ticles was conducted to determine how much drug may be
released during the setting phase of composite formation.
For this purpose, 10 mg of washed PLGA particles were
incubated at 37° C. in 1 mL of phosphate-buffered saline
(PBS), pH 7.4. Supernatant was collected and replaced with
fresh PBS every 15 min for the first hr, every 30 min for the
2nd hr, every hr for the 3rd and 4th hr, and finally increased
to every 2 hr for the 6'h and 8'h hr time points. Supernatants
were filtered (0.45 µm) and the absorbance measured at 318
nm.
Bilayered Calcium Sulfate Composites
Fabrication of the bilayered composites is illustrated in
FIG. 1. The composites consisted of calcium sulfate hemi
hydrate (Sigma-Aldrich) as the structural matrix. First, blank
CS samples without layers were produced by combining 1 g
of CS with 800 µL of deionized (DI) water. The slurry was
injected into a mold having a diameter of 6.3 mm and a
height of 12.6 mm. The loaded mold was placed in a 43 ° C.
oven for 24 hr to allow for the CS to completely set.
To begin formation of bilayered composites, cylindrical
cores were produced in Teflon molds having a diameter of
4.7 mm and a height of 10 mm. A small, 8 mm long metal
peg with a 0.63 mm diameter was fitted precisely in the
center of the mold, with about 2.5 mm of the peg embedded
into the core. The pegs suspended and centered the cores for
shell production later. To make blank CS cores, 800 µL of DI
water was added to 1 g of CS powder and mixed thoroughly
in 3 mL non-sterile syringes fitted with a 16 gauge blunt
needle. The slurry was loaded into the custom-fabricated
Teflon mold and placed in a 43 ° C. oven for 24 hr to set the
CS. For cores loaded with simvastatin, the same process was
used, however 20 mg of simvastatin (Haouri Pharma-Chem,
Inc., Edison, N.J.) were mixed along with the CS and DI
water. Pegs were removed from the cores when they were
dried, and the cores were stored at room temperature with
desiccant until used.
To form the shell around the cores, another Teflon mold
was created with cylindrical holes having the diameter of 6.3
mm and a height of 12.6 mm. The base plate was fabricated
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with 3.5 mm deep holes into which metal pegs were securely
inserted. This depth allowed the cores to be positioned
precisely in the center of the mold, thus allowing the shell
to surround the core. Blank and simvastatin-loaded shells
were created using the same method described above for the
cores, where 1 g of CS was mixed with 800 µL of DI water,
and in the case of simvastatin-loaded shells, 20 mg of drug
were directly added. For samples containing metronidazole
loaded PLGA, the particles were added to both the blank and
simvastatin-loaded shells at either 1 or 10 wt % and then
mixed with 850 µL DI water in 3 mL syringes fitted with a
blunt-tipped needle for easy, consistent filling of the mold.
Using these formulations for the shells, bilayered compos
ites were formed by filling the molds about half full. Next,
prefabricated cores were quickly dipped in DI water to wet
the surface, which allowed for smooth coverage of the shell
slurry around the core, inserted into the mold, and pressed
down onto the metal pegs until they stopped. The pegs
positioned the cores and held them in place during setting of
the shell slurry. The filled mold was placed into a 37° C.
oven and allowed to dry overnight. For simplification, the
different types of samples were given abbreviated names
(Table 1).
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TABLE 1
Abbreviations for tbe different sample types fabricated.
Codes are read: BSBC » (B)S(B)C » (Loading) in SHELL,
(Loading) in CORE.
Shell Composition

Core Composition

Code

Blank
Blank
Simvastatin
Simvastatin
1 wt% PLGA
1 wt% PLGA
1 wt% PLGA & Simvastatin
1 wt% PLGA & Simvastatin
10 wt% PLGA
10 wt% PLGA
10 wt% PLGA & Simvastatin
10 wt% PLGA & Simvastatin
No Layer Blank (No Drug)

Blank
Simvastatin
Blank
Simvastatin
Blank
Simvastatin
Blank
Simvastatin
Blank
Simvastatin
Blank
Simvastatin

BSBC
BSSC
SSBC

sssc

1-BSBC
1-BSSC
1-SSBC
1-SSSC
10-BSBC
10-BSSC
10-SSBC
10-SSSC
NL

Note:
PLGA particles contained metronidazole.
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The shells and cores described had a volume ratio of
50:50. Two other ratios were tested with simvastatin loaded
into the shell only (SSBC), core only (BSSC), or both layers
(SSSC). These samples were used to demonstrate how a
change in the volume ratio would affect drug release from
the composites. Table 2 lists the volume ratios used and the
dimensions of the respective core and shell components.
Custom molds were created to accommodate the different
sizes, but the rest of the fabrication process was the same as
described previously.
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TABLE 2
Shell to core volume ratios and dimensions of
the bilayered composites

60

Volume Ratio

Shell Height

Shell
Diameter

Core Height

Core
Diameter

50:50
70:30
85:15

12.6 mm
9.6 mm
9.6 mm

6.3 mm
4.7 mm
4.7 mm

10 mm
6.2 mm
6.2 mm

4.7 mm
3.2 mm
2.4 mm
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Composite Microarchitecture
To monitor the distribution of PLGA particles within the
CS shell matrix as well as the interface between shell and
core, microcomputed tomography (microCT) was
employed. Using a Scanco Medical µCT-40 scanner, speci
mens were evaluated at high resolution. Other parameters
were set as follows: 156 µm increments, 0° angle, 70 kVp,
114 µA, 0.5 mm Al filter, and a voxel size of 8 µm. The raw
images were qualitatively investigated for particle distribution trends, core orientation, and shell-core interaction. In
addition, qualitative and quantitative assessment of the
composites was conducted using a built-in 'bone trabecular
morphometry' analytical tool with a lower threshold level of
130, gauss sigma of 3.0, and gauss support of 9. This script
created a three-dimensional reconstruction that allowed
visual assessment of cross-sections through the composite
and provided the volume percentage of embedded polymeric
particles and internal voids.
Composite Dissolution
Destructive testing was used to monitor dissolution of the
bilayered composites. BSBC, 1-BSBC, and 10-BSBC
samples were weighed, placed in separate 20 mL scintilla
tion vials containing 12 mL of PBS and incubated on a plate
shaker at 37° C. Every 4 d, replicate samples of each type
were removed and dried at 43° C. overnight. For the
remaining samples, the PBS was replaced with fresh solu
tion. The dried samples were weighed to determine the
amount of material remaining, which was then used to
calculate the percentage of residual mass.
Mechanical Properties
Compression testing was performed to investigate any
effects on mechanical properties caused by the layered
geometry, simvastatin directly loaded into CS as well as the
introduction of PLGA particles into the shell of the com
posites. All samples types listed in Table 1 were evaluated.
Testing was accomplished using a Bose ELF 3300 system.
Contact surfaces were lightly sanded, if necessary, to create
parallel surfaces in contact with the compression platens. All
samples were loaded at a rate of 0.5 N/sec until failure.
Compressive modulus (M) and ultimate compressive
strength (UCS) were calculated (Dowling N E. Mechanical
behavior of materials: engineering methods for deformation,
fracture, and fatigue. 2 ed. Upper Saddle River, N.J.: Pren
tice-Hall; 1999).
Drug Release from Bilayered Composites
Simvastatin Release
Release of simvastatin was measured for composites
having shell to core volume ratios of 50:50, 70:30, and
85:15. BSBC, BSSC, SSBC, and SSSC samples for all
volume ratios were prepared using the same simvastatin
loading described in section 2.2. Samples were pre-weighed
and submerged in PBS. Considering the overall size differ
ences between the sample types, different volumes of PBS
were used to maintain similar fluid volume to composite
surface area ratios. To determine suitable sink conditions,
the sample surface area to solution volume ratio of 50:50
samples was compared to those used in previous research
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino
ester) hydrogel composites. J Mech Behav Biomed. 2013;
26:43-53). A small pilot study showed that the dissolution
rate of 50:50 samples remained constant for volumes above
10 mL (data not shown). To avoid saturation of CS or drug
in PBS, a larger volume (12 mL) was used for the 50:50
samples. All other samples were placed in 4 mL, similar to
previous release studies (Oreliana B R, Hilt J Z, Puleo D A.
Drug release from calcium sulfate-based composites. J
Biomed Mater Res B. 2014). To determine how simvastatin
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would be released from bilayered composites dissolving in
non-sink conditions, 50:50 samples were also immersed in
8 mL of PBS. All samples were incubated at 37° C. on a
plate shaker. Every 4 d, supernatant was collected and
replenished with fresh PBS. Collected supernatant was
treated with 100% ethanol in a 50:50 volume ratio to make
sure all simvastatin was in solution. The mixture was then
0.45 urn-filtered and absorbance measured at 240 nm.
Multiple Drug Release
To investigate the kinetics of metronidazole and simvastatin release from bilayered CS composites, samples were
pre-weighed, submerged in 12 mL of PBS, and incubated at
37° C. while on a plate shaker. Supernatant was collected
and replenished every 4 d. Two aliquots from each sample
were kept for measurement of metronidazole and simvasta
tin separately. Metronidazole in syringe-filtered (0.45 µm)
supernatant was assayed directly using UV spectroscopy at
318 nm. Simvastatin was measured using high performance
liquid chromatography (HPLC) on a Hitachi Primaide sys
tem fitted with a Kinetix C18 column (5 µm, 4.6x150 mm).
Prior to measurement, supernatant was mixed with 5 mM
EDTA (pH 8.0) at a 50:50 volume ratio and allowed to sit
overnight. EDTA, a common chelating agent, was used to
remove calcium ions that could precipitate during HPLC
analysis. Next, this mixture was mixed with 100% ethanol in
a 50:50 volume ratio to ensure complete dissolution of the
poorly soluble simvastatin. The final sample composition
was 25% supernatant, 25% EDTA, and 50% ethanol. A
70:30 (acetonitrile: DI water+0.01% trifluoroacetic acid)
isocratic mobile phase at a flow rate of1 mL per minute was
used. Simvastatin was detected at 240 nm.
Statistics
Statistical analysis of the results was conducted using
either a two-tailed unpaired t-test or one-way ANOVA. As
appropriate, a Tukey-Kramer multiple comparison post hoc
test was implemented. Linear regression was performed on
sustained release profiles and the calculated slopes com
pared for significant differences using a two-tailed t-test.
Differences between groups were considered to be signifi
cant with p-values <0.05.
Metronidazole-Loaded PLGA Particles
Metronidazole-loaded PLGA particles alone were first
evaluated to determine how well the polymer controlled
drug release. According to the results in FIG. 2, metronida
zole was released steadily during the first 3 hr at a rate of
about 4 µg per minute. Only about 8% of the drug was
released during the first hr. After 3 hr, 30% of the total
loading of metronidazole had been released. From this point
forward, the release of drug from the particles slowed, with
roughly 35% ofthe loaded metronidazole released after 6 hr.
Composite Microarchitecture
Qualitative Evaluation
MicroCT images showed the CS cores embedded within
the layered composites and their interaction with the CS
shells, as well as the distribution of PLGA particles embedded in the shells (FIG. 3). For comparison, results for a CS
sample without layers (NL) are included. Minor defects
(bubbles and other discontinuities) were found throughout
the CS matrix in all samples. These defects were nearly
spherical in nature and, thus, easily distinguishable from
PLGA particles, which were irregularly shaped. The blank
(drug-free) layered samples, BSBC, showed the CS core
embedded within the CS shell and oriented parallel to the
outer walls. The distribution of1 wt % PLGA particles in the
shells of 1-BSBC samples appeared to be homogeneous but
sparse (FIG. 3, top right). In 10-BSBC samples with 10 wt
% loading of particles in the shells, there was a homage-
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neous but more frequent distribution of particles throughout
the CS shell (FIG. 3, bottom right). Similar to BSBC, both
1-BSBC and 10-BSBC had cores that were embedded in the
center of the composite with a parallel orientation to the
outer surface. Additionally, all layered samples had some
minor defects located at the shell/core interface, with most
ofthese discontinuities occurring near the top and bottom of
the samples.
Quantitative Evaluation
Morphometric analysis was conducted to better assess the
overall microarchitecture of bilayered CS samples. As
shown in FIG. 4, the average volume percentage of voids in
NL samples (0.96%) was significantly lower than that for all
others (p<0.001). Furthermore, the particle content of
10-BSBC samples, 7.59%, was significantly higher
(p<0.001) than that ofboth BSBC and 1-BSBC. Percentages
for BSBC (3.30%) and 1-BSBC (4.52%) were not signifi
cantly different.
Composite Dissolution
Loading 1 wt % of PLGA particles into the shells of
bilayered composites did not have a significant effect on the
dissolution rate (-3.1%/d) (FIG. 5). Increasing the loading to
10 wt % PLGA, however, significantly increased the disso
lution rate to -3.43%/d (p<0.001), even though the time for
complete dissolution differed by only about 4 d.
Mechanical Properties of Layered CS
Fabrication oflayered structures significantly affected the
mechanical properties of CS composites (FIG. 6). The
ultimate compressive strength of NL (5.40±0.38 MPa)
samples was not significantly higher than that of BSSC
(4.14±0.75 MPa) and 1-BSBC (4.33±0.72 MPa), but it was
significantly greater than that for BSBC (3.80±0.46 MPa,
p<0.01) and all other bilayered samples (p<0.001) (FIG.
6A). Within subgroups for PLGA particle loading, the
strength of 1-BSBC (4.33±0.72 MPa) was significantly
higher than that for both 1-SSSC (3.03±0.2 MPa) and
10-BSSC (3.03±0.4 MPa) (p<0.05). There were no other
significant differences seen for layered samples, both loaded
with PLGA and without.
The compressive elastic modulus ofNL (712±139.6 MPa)
was significantly higher (p<0.001) than that for SSBC
(250±37.6 MPa), 1-BSBC (172±96.9 MPa), 1-SSSC
(162±70.4 MPa), 10-BSBC (237±84.2 MPa), 10-BSSC
(154±58.4 MPa), 10-SSBC (216±87.8 MPa), and 10-SSSC
(184±29.6 MPa) bilayered samples (FIG. 68). The average
modulus of the blanks was also significantly greater than
those of SSSC (306±157.6 MPa, p<0.01) and 1-SSBC
(391±282 MPa, p<0.05). BSSC (495±184 MPa) samples
had a significantly higher (p<0.05) modulus than did
1-BSBC (172±97 MPa), 1-SSSC (162±70 MPa), and
10-BSSC (154±58 MPa). There were no other significant
differences between layered samples and their subgroups.
Drug Release from Bilayered Composites
Simvastatin Release
To demonstrate temporally controlled release of simvas
tatin using bilayered composites, several experiments were
conducted using different shell to core volume ratios. FIG.
7A shows the cumulative release of simvastatin from com
posites that had an 85:15 shell to core volume ratio. The
sustained release of drug from samples with simvastatin
loaded into both shell and core (SSSC), 0.055 mg/d, was
significantly faster (p<0.001) than for SSBC (0.043 mg/d)
and SSBC+BSSC (0.046 mg/d). Minimal drug loaded into
the core only (BSSC) was released during the first 24 d.
From that point until the samples dissolved, however,
release of simvastatin from CS cores increased to 18 µg/d,
whereas release from SSBC samples was finished. The total
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amount of simvastatin released from BSSC (shell) and
SSBC (core) samples was 0.24±0.05 mg and 1.19±0.01 mg,
respectively. The rate of release from BSSC was signifi
cantly slower than that for both SSSC (p<0.05) and SSBC+
BSSC (p<0.01).
FIG. 78 shows the results for simvastatin released from
composites consisting of 70% shell volume and 30% core
volume. Over the first 20 d, the drug release rate from SSBC
(0.046 mg/d) was significantly faster (p<0.01) compared to
0.041 mg/d for SSSC. Little to no drug was released from
BSSC samples during the first 20 d, followed by an upward
shift to a rate of 0.022 mg/d, which was significantly slower
than the rates for both SSSC and SSBC+BSSC (p<0.01). For
BSSC samples, 0.32±0.03 mg of drug was released. After 20
d of simvastatin release from SSBC samples, the shells had
completely dissolved and released 1.30±0.07 mg of simv
astatin.
The results for release of simvastatin from composites
with a 50:50 shell to core volume ratio are depicted in FIG.
7C. For the first 16 d of the experiment, the rate of release
from SSBC composites, 0.095 mg/d, was significantly
slower (p<0.05) than that for SSSC (0.13 mg/d) and SSBC+
BSSC (0.12 mg/d). During the same period, a small amount
of drug was released from BSSC at a slow rate of 0.025
mg/d. After 16 d and until the composites dissolved, the rate
of drug release from SSBC samples gradually slowed as the
shell finished dissolving, a trend similar to what was
observed in both FIGS. 7A and 78. A total of 1.52±0.3 mg
of drug was released from the shell. At its peak, the rate of
release from BSSC samples, 0.10 mg/d, was not signifi
cantly different from the rates observed for SSSC and
SSBC+BSSC samples, ultimately releasing a total
1.44±0.24 mg of simvastatin.
The total amount of simvastatin released from the cores
(BSSC) for 50:50 (1.44±0.24 mg) samples was significantly
different (p<0.001) than that for samples with either a 70:30
(0.32±0.03 mg) or 85:15 (0.24±0.05 mg) shell to core
volume ratio. There was no significant difference in the total
drug release between the 70:30 and 85:15 BSSC samples.
For 50:50 SSBC samples, the total amount released
(1.52±0.3 mg) from the shells was significantly different
(p<0.001) than for 70:30 SSBC (1.30±0.07 mg) and 85:15
SSBC (1.19±0.1 mg) samples. In addition, the total amount
of drug released from 70:30 SSBC samples was significantly
different than from 85:15 SSBC samples (p<0.01). When
comparing the total amount of drug released when SSBC
and BSSC results are combined (SSBC+BSSC) to the total
amount of drug released from SSSC samples, SSBC+BSSC
specimens with an 85:15 shell to core volume ratio had a
total combined release that was significantly lower (p<0.01)
than the total amount of simvastatin released from the SSSC
with the same volume ratio.
By reducing the volume of PBS from 12 mL to 8 mL, the
dissolution time of samples having a 50:50 shell to core ratio
was doubled (FIG. 8). During the first 32-36 d of incubation,
simvastatin was released from both SSSC and SSBC
samples at a rate of 0.074 mg/d and 0.077 mg/d, respec
tively. Also, a small amount of drug from BSSC samples was
released during the same time frame at a rate of 0.009 mg/d.
From day 36 until the end of the experiment (68 d), the rate
for the SSSC samples continued steadily, however the rate
of release from SSBC decreased to zero around 48 d.
Additionally, the rate of release from BSSC samples
increased to 0.051 mg/d and remained at this rate until the
samples finished eroding.

5

10

15

20

25

30

35

40

45

50

55

60

65

16

Multiple Drug Release
FIG. 9 shows results for release of metronidazole from
PLGA particles embedded in CS shells as well as the release
of simvastatin directly loaded in the shell or core of bilayered composites. The samples used for this experiment had
a 50:50 shell to core volume ratio. Based on this ratio and
the dissolution results presented in FIG. 5, the shell and core
portions of the composites were predicted to dissolve com
pletely in 14-16 d of the 28-32 d dissolution period for the
complete composite. For composites with 1 wt % PLGA
particles embedded in CS, a large amount of metronidazole
(65%) was initially released from the shells during the first
4 d at a rate of 16.3%/d (FIG. 9A). After the initial burst of
metronidazole, the release of drug slowed to a rate of 4.0%/d
and continued to slowly decay to zero until the shells
completely dissolved. Composites with 10 wt % PLGA
particles showed a similar burst of metronidazole during the
first 4 d, with as much as 55% of the total drug released
(FIG. 98). The rate of release of metronidazole decayed
from 13.7%/d through the first 4 d, to 6.7%/d from days 4-8,
and finally down to 0% by d 12 of the release. The results
in FIG. 9 were normalized based on the amount of drug
loaded into the respective layer rather than the complete
composite. This allowed for direct comparison of the tem
poral release observed between metronidazole and simvastatin. When simvastatin was loaded into only the shell for 1
wt % and 10 wt % PLGA composites, metronidazole was
initially released at a higher rate than simvastatin (2-6.3%/
d). Because of the slow initial rate of simvastatin release, a
short lag in the release profile developed, creating separation
from the metronidazole profile and allowing for simvastatin
to be released for up to 8 d longer. When the drugs were
separated by keeping metronidazole-containing PLGA par
ticles in the shell and loading simvastatin in only the core,
80-90% of the metronidazole was released over approximately 12 d before trace amounts of simvastatin were
detected. After 16 d, the shells had completely dissolved,
and metronidazole was no longer detected. In addition, the
majority of simvastatin, isolated to only the core, was
released starting after 12 d. Due to the layers separating the
two drugs, a sequential release was observed with all met
ronidazole drug released prior to simvastatin.
Metronidazole-Loaded PLGA Particles
A previous study showed that loading a hydrophilic drug
into carrier particles prior to embedding into a CS matrix
significantly reduced the burst release witnessed when the
drug was directly loaded into CS (Oreliana B R, Hilt J Z,
Puleo D A. Drug release from calcium sulfate-based com
posites. J Biomed Mater Res B. 2014). Therefore, biode
gradable PLGA microparticles were employed for the cur
rent study to assist with the sustained release of
metronidazole from bilayered composites. Because the particles were exposed to water during the setting phase of CS,
a release study was conducted using a larger volume of
water than present during composite formulation to monitor
the potential for premature release of drug from PLGA. No
initial burst of drug was observed, indicating that the major
ity of the drug was contained within the PLGA micropar
ticles during the formation of the composites.
Composite Microarchitecture
Qualitative assessment of the morphology of bilayered
composites showed good distribution of PLGA micropar
ticles embedded into CS shells at 1 and 10 wt %. The initial
CS slurry was kept sufficiently fluid to prolong the working
phase and allow for easy filling of the molds yet viscous
enough to suspend PLGA particles during the setting phase.
This trend has been shown in previous research in which
hydrogel particles were uniformly distributed throughout a
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CS matrix using similar powder to liquid volume ratios
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino
ester) hydrogel composites. J Mech Behav Biomed. 2013;
26:43-53). Another study, showed the exposure of particles
at or near the surface before dissolution followed the pitting
of CS resulting from the release of particles from those
locations after a short duration submerged in PBS (Oreliana
B R, Hilt J Z, Puleo D A. Drug release from calcium
sulfate-based composites. J Biomed Mater Res B. 2014).
With the aid of small, metallic pegs, which were removed
after fabrication, preformed blank and simvastatin-loaded
cores were positioned in the center of the composites. Small
defects were observed along the shell/core boundary. Many
of these were air bubbles trapped as the CS set. Larger
bubbles that appeared to accumulate near one end of the
samples along the shell/core interface were most likely
caused by an air pocket created when the cores were pressed
into CS slurry.
Quantitative measurements assessed the particle volume
fraction of bilayered CS composites. Although a significant
increase in porosity was seen between samples containing 1
wt% and 10 wt% PLGA, the difference was not 10-fold.
This lack of separation could be due to other defects, such
as air pockets found along the shell/core interface. The script
used to calculate the porosity is limited to only distinguish
ing between what is solid and what is not. The introduction
of bubbles adds error to the calculations because these
imperfections show up as radiolucent spaces similar to
PLGA particles. Comparing the solid and layered samples
demonstrates that defects strongly influenced on the porosity
calculations.
Composite Dissolution
Calcium sulfate is a dense material that dissolves via
surface erosion (Oreliana B R, Thomas M V, Dziubla T D,
Shah N M, Hilt J Z, Puleo D A. Bioerodible calcium
sulfate/poly(�-amino ester) hydrogel composites. J Mech
Behav Biomed. 2013; 26:43-53; Thomas M V, Puleo D A.
Calcium sulfate: properties and clinical applications. J
Biomed Mater Res B. 2009; 8 8 6:597-610). Although the
embedded PLGA particles were distributed throughout the
CS matrix, they did not appear to be interconnected, which
otherwise would have allowed for fluid to seep into the
composite. During erosion, closed pockets with PLGA par
ticles near the surface were exposed, releasing the polymer
particles and increasing the surface area for further disso
lution. Consequently, as the composites dissolved and
PLGA particles were released, the surface area to volume
ratio increased, allowing for faster dissolution of CS. Fur
thermore, because embedded PLGA particles did not change
the dissolution characteristics of CS, the shorter lifespan
when 10 wt % particles were added was related to the
smaller overall volume of CS per sample that needed to
dissolve. These trends have also been witnessed in a previ
ous study in which dissolution of CS was observed after
hydrogel particles were uniformly distributed throughout the
composite (Oreliana B R, Thomas M V, Dziubla T D, Shah
N M, Hilt J Z, Puleo D A. Bioerodible calcium sulfate/poly
(�-amino ester) hydrogel composites. J Mech Behav
Biomed. 2013; 26:43-53). Thus, the presence of polymer
particles, even having different chemistries, affected only the
duration of dissolution, depending on the amount of par
ticles loaded, and not the nature of the dissolution process
itself.
Mechanical Properties of Layered CS
To be a suitable alternative to autologous bone, the ideal
synthetic material would have characteristics similar to
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those of tissue at the implantation site. CS has been
described as having properties being similar to cancellous or
trabecular bone (Hak D J. The Use of Osteoconductive Bone
G raft Substitutes in Orthopaedic Trauma. JAmAcad Orthop
Sur. 2007; 15:525-36). Investigating the mechanical prop
erties of human trabecular bone from the mandible, Misch et
al. measured an ultimate compressive strength of 3.9±2.7
MPa and elastic modulus of 96.2±40.6 MPa (Misch CE, Qu
Z, Bidez M W. Mechanical properties of trabecular bone in
the human mandible: Implications for dental implant treat
ment planning and surgical placement. J Oral Maxi! Surg.
1999; 57:700-6). The introduction of a bilayered geometry
significantly affected properties compared to solid CS
samples, with up to a 44% and 78% reduction in the strength
and elastic modulus, respectively. Note, however, that the
properties of the layered composites were comparable to
those of trabecular bone. The decrease in strength compared
to the samples without layers could be due to the small air
pockets along the shell/core interface acting as discontinui
ties within the composite, both at the interface parallel to the
central axis of the cylinder as well as at the ends of the core.
These stress concentrators contributed to a 17-44% decrease
in the overall strength of the composites. The addition of
either 1 or 10 wt% PLGA particles to CS shells did not have
an effect when compared to blank bilayered samples. In
previous research, as much as a 50-60% reduction in
strength was seen following the addition of 10 wt% of gel
particles to the monolithic CS matrix (Orellana BR, Thomas
M V, Dziubla T D, Shah N M, Hilt J Z, Puleo D A.
Bioerodible calcium sulfate/poly(�-amino ester) hydrogel
composites. J Mech Behav Biomed. 2013; 26:43-53). In the
present study, the PLGA particles were isolated to only the
shell of the composites. Also, the presence of a solid blank
core may have provided reinforcement for the composite,
which may allow a greater range of PLGA particle loading
that would provide greater control over the drug dose within
the composites.
The loading of simvastatin directly into the shell, core, or
both layers generally did not significantly affect the strength
of the bilayered composites, even though isolated differ
ences were observed (1-BSBC versus 1-SSSC and
10-BSSC). In another experiment conducted by Oreliana et
al., loading of simvastatin directly into monolithic CS did
not have a significant effect on the strength of the samples
(Oreliana B R, Hilt J Z, Puleo D A. Drug release from
calcium sulfate-based composites. J Biomed Mater Res B.
2014). Another group determined that up to 10% loading of
simvastatin into calcium phosphate samples did not signifi
cantly affect the compressive strength (Yin H, Li Y G , Si M,
Li J M. Simvastatin-loaded macroporous calcium phosphate
cement: Preparation, in vitro characterization, and evalua
tion of in vivo performance. J Biomed Mater Res A. 2012;
lOOA:2991-3000). The present study had a lower loading of
simvastatin (i.e., 2 wt%), however. Thus, direct loading of
simvastatin does not affect the overall strength of different
materials.
Drug Release from Bilayered Composites
The layered geometry used for the CS samples provided
a unique platform for achieving a customizable sequential
release of therapeutic agents. Loading of PLGA micropar
ticles into the CS matrix allows for further tailoring of drug
release.
Simvastatin Release
The present experiments were designed to demonstrate
how the release of simvastatin can be tailored depending on
which layer the drug was loaded in, whether it was the shell
only, core only, or both. Furthermore, to illustrate the ability
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to adjust the duration or even the delay of drug release from
either the shell or core, the shell to core volume ratio was
altered. However, there were limitations to how much the
volume ratio could be adjusted.For instance, the 50:50 shell
to core ratio was considered the maximum. With the present
dimensions, increasing the core volume beyond this point
would create a thin and unstable shell. On the other hand, if
the ratio was made so the shell would be greater than 85%
of the total volume, the local concentration of drug released
from the core could be too low to be therapeutically relevant.
For all of the release profiles that had simvastatin loaded
in only the cores, there was a small amount of drug released
from the start of composite dissolution up to when the core
was completely exposed. Because the cores were suspended
using a small metal peg that was later removed after the
samples were fabricated, the hole that remained may have
been large enough to allow a noticeable, but statistically
insignificant, amount of simvastatin to be released.
In addition to investigating the effects of adjusting the
shell to core volume ratio, the volume of PBS used for the
release study was reduced from 12 mL to 8 mL. Because of
the possible diverse environments in various implantation
sites, it is likely for the implant to encounter different fluid
volumes and/or turnover rates that may not allow for sink
conditions. A small study demonstrated how release of
simvastatin would change under non-sink conditions. To
conduct the comparison, the 50:50 volume ratio was used.
Interestingly, even with the reduction in the volume of PBS
to 8 mL, the transition after shell depletion to core only
erosion occurred around the halfway point, similar to the
results seen under sink conditions. In previous work, the
effects of fluid volume on the dissolution of CS were
investigated (Orellana BR, Thomas M V,Dziubla TD, Shah
N M,Hilt J Z, PuleoDA. Bioerodible calcium sulfate/poly
(�-amino ester) hydrogel composites. J Mech Behav
Biomed. 2013; 26:43-53). It was determined that the change
in volume of fluid or even the turnover rate could have a
large effect on the dissolution of CS (Orellana BR, Thomas
M V, Dziubla T D, Shah N M, Hilt J Z, Puleo D A.
Bioerodible calcium sulfate/poly(�-amino ester) hydrogel
composites. J Mech Behav Biomed. 2013; 26:43-53). The
duration of drug release can be greatly prolonged (doubled
in the present study) using different fluid volumes. McLaren
et al. also observed a large difference in the rate of drug
release from calcium sulfate pellets when the fluid was
completely refreshed at each time point versus exchanging
only a fraction of the fluid volume (McLarenA C, McLaren
S G , Nelson C L, Wassell D L, Olsen K M. The effect of
sampling method on the elution of tobramycin from calcium
sulfate. Clinical orthopaedics and related research. 2002:547). In the present study, although the rate of release slowed,
the mechanism of drug release remained dependent on
dissolution of CS. This could allow for tailoring of drug
loading and/or the sample geometry according to the physi
ological conditions expected at the implant site.
Multiple Drug Release
A multiple drug release study was conducted to investi
gate the release kinetics of bilayered composites loaded with
an antimicrobial agent and an osteogenic agent. Findings for
samples with metronidazole in PLGA particles and simvastatin directly loaded into CS demonstrated sequential
release. Polymeric particles loaded with metronidazole and
embedded into the shell were exposed as CS experienced
surface erosion, and sustained release of the drug occurred
as the PLGA particles subsequently degraded. Release from
both 1 and 10 wt % particles embedded into the CS shell was
sustained until the shell portion of the bilayered composites
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completely dissolved. Controlled release of metronidazole
from PLGA microspheres after an initial burst has been
described as a possible treatment for periodontal disease
(Tiwari G . Treatment Of Periodontal Diseases:Formulation
consideration. Int J Phann Bio Sci). By embedding particles
into a CS matrix, the release of metronidazole was controlled throughout the first 16 d of the present study. In
addition, previous research has demonstrated that drug
loaded hydrogel particles homogeneously distributed
throughout a CS matrix allowed for a controlled release of
drug, which only occurred due to the breakdown of particles
exposed at the surface of the dissolving composite (Orellana
B R, Thomas M V, Dziubla T D, Shah N M,Hilt J Z, Puleo
D A. Bioerodible calcium sulfate/poly(�-amino ester)
hydrogel composites. J Mech Behav Biomed. 2013; 26:4353; Orellana B R, Hilt J Z, Puleo DA. Drug release from
calcium sulfate-based composites. J Biomed Mater Res B.
2014).
With the intended use of these composites as a grafting
substitute for alveolar bone augmentation, the oral cavity
presents challenges for proper tissue regeneration due to the
environment being rich with bacteria that can colonize
natural and synthetic substrates. Thomas and Puleo
described the implications of infection and inflammation in
periodontal disease and tissue regeneration (Thomas M,
PuleoD. Infection, Inflammation, and Bone Regeneration a
Paradoxical Relationship. J Dent Res. 2011; 90:1052-61).
Currently, the standard treatment for infected periodontal
defects has antimicrobial agents being administered, either
systemically or locally, prior to implantation of grafting
material, which only delays the overall recovery of lost
tissue (Nguyen A, Kim S, Maloney W, Wenke J, Yang Y.
Effect of coadministration of vancomycin and BMP-2 on
cocultured Staphylococcus aureus and W-20-17 mouse bone
marrow stromal cells in vitro.AntimicrobAgents Ch. 2012;
56:3776-84; LeeF-Y, ChenD,Hu C-C,Hsieh Y-T, Liu S-J,
Chan E-C. In Vitro and In Vivo Investigation of Drug
Eluting Implants for the Treatment of Periodontal Disease.
AAPS PharmSciTech. 2011; 12:1110-5; Bernimoulin J P.
Repeated local metronidazole-therapy as adjunct to scaling
and root planing in maintenance patients. J Med Microbial.
1999; 26:710-5). Administration of antimicrobial agents
allows for better bone formation. Chen et al. investigated the
effects of two different growth factors in a chronically
infected bony defect in rat femurs (Chen X, Schmidt AH,
Tsukayama D T, Bourgeault CA, Lew W D. Recombinant
Human Osteogenic Protein-I Induces Bone Formation in a
Chronically Infected, Internally Stabilized Segmental
Defect in the RatFemur. J Bone Joint Surg. 2006; 88:151023). Although some healing occurred in the infected sites,
the extent of bone formation was greater with the systemic
administration of antibiotics (Chen X, Schmidt A H, Tsu
kayama D T, Bourgeault C A, Lew W D. Recombinant
Human Osteogenic Protein-I Induces Bone Formation in a
Chronically Infected, Internally Stabilized Segmental
Defect in the Rat Femur. J Bone Joint Surg. 2006; 88:151023). To further enhance the process of fighting infection and
then regenerating lost tissue, release of an anti-bacterial
agent from the graft starting at the time of implantation may
prove beneficial to help reduce the overall healing time.
Many studies have investigated dual purpose implantable
scaffolds, but none have employed a concentric cylindrical
CS system as described in the present studies. Reis et al.
developed drug-free, bilayered membranes comprising a
continuous outer layer of PLGA with a porous calcium
phosphate inner layer for the regeneration of lost periodontal
tissue (CarloReis E C, BorgesA P B,Araujo M VF, Mendes
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V C, Guan L, Davies J E. Periodontal regeneration using a
bilayered PLGA/calcium phosphate construct. Biomaterials.
2011; 32:9244-53). For infected sites, Nguyen et al. devel
oped a co-culture model using methicillin-sensitive Staphy
lococcus aureus and mouse bone marrow stromal cells to
investigate the dual effects of an antibiotic, vancomycin,
along with bone morphogenetic protein-2 (BMP-2) (Nguyen
A, Kim S, Maloney W, Wenke J, Yang Y. Effect of coad
ministration of vancomycin and BMP-2 on cocultured
Staphylococcus aureus and W-20-17 mouse bone marrow
stromal cells in vitro.AntimicrobAgents Ch. 2012; 56:377684). Separately, the two agents were not effective, but when
delivered together, the needed concentration of vancomycin
was significantly reduced, suggesting that lower, non-toxic
doses could be used (NguyenA, Kim S, Maloney W, Wenke
J, Yang Y. Effect of coadministration of vancomycin and
BMP-2 on cocultured Staphylococcus aureus and W-20-17
mouse bone marrow stromal cells in vitro. Antimicrob
Agents Ch. 2012; 56:3776-84). An in vivo study in which
vancomycin and BMP-2 were delivered simultaneously
from a biodegradable polyurethane scaffold demonstrated
that bone formation could be regenerated within an infected
defect (Guelcher S A, Brown KV, Li B, Guda T, Lee B H,
Wenke J C. Dual-purpose bone grafts improve healing and
reduce infection. J Orthop Trauma. 2011; 25:477-82). However, these systems release the drugs simultaneously. Con
sidering the intent for the current device to help streamline
the existing treatment process, it was encouraging to see
metronidazole released before simvastatin, even when
loaded into the shell together. The difference in the release
kinetics can be explained primarily by the way the two drugs
were loaded. Previous work has shown that release of drug
from polymer particles embedded into a CS matrix had a
rapid, initial burst followed by decay in the rate of release
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino
ester) hydrogel composites. J Mech Behav Biomed. 2013;
26:43-53; Oreliana B R, Hilt J Z, Puleo D A. Drug release
from calcium sulfate-based composites. J Biomed Mater Res
B. 2014). The lower rate is attributed to the decrease in
surface area as CS degrades, leading to a smaller volume of
particles exposed at the surface over time (Orellana B R,
Thomas MV, Dziubla T D, Shah N M, Hilt J Z, Puleo DA.
Bioerodible calcium sulfate/poly(�-amino ester) hydrogel
composites. J Mech Behav Biomed. 2013; 26:43-53; Orellana B R, Hilt J Z, Puleo D A. Drug release from calcium
sulfate-based composites. J Biomed Mater Res B. 2014).
Simvastatin, on the other hand, is directly mixed with CS
during sample formation, and due to the hydrophobic nature
of the drug, it does not become segregated to the surface
during the setting of CS. The release of simvastatin is,
therefore, governed by the surface erosion characteristics of
CS, which were shown to be linear. This allowed for a near
constant rate of release of simvastatin. These differences in
release kinetics between the two drugs and their means of
loading allowed for enough separation for all the metron
idazole to be released 4 d sooner than simvastatin. When
simvastatin was loaded into only the core while PLGA
particles loaded with metronidazole remained in the shell,
there was a much greater lapse in time for a fully separated
sequential release to occur, which may be useful for mim
icking the clinical sequence of events for treating infection
and subsequently restoring lost or damaged tissue.
In the present study, novel bilayered CS composites were
investigated for their ability to provide tailored release of
therapeutic agents as well as a sequential release of different
drugs. Such a system may be useful as a bone graft substitute
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for treating infected bony defects, e.g., periodontal pockets.
Although the shell and core geometry reduced mechanical
strength of the composites, the properties were similar to
those for mandibular trabecular bone. This may be an
important trait that could allow for these implants to better
mimic the surrounding target tissue being treated. Changing
the shell to core volume ratio dictates the duration of drug
release from each layer. W hen metronidazole and simvas
tatin were loaded together in the shell or in separate layers,
temporal separation of the two drugs was achieved. Being
able to tune such as system may help streamline the multiple
steps needed to regenerate tissues more efficiently.
Example 2
Blank Samples
Bilayered calcium sulfate (CS) composites were produced
according to FIGS. 1 and 10. CS slurries were prepared by
mixing 1 gram CS powder with 800 µL of deionized water
(DI). To create cores, prepared CS slurry was injected into
a Teflon mold and kept at 43 ° C. for 24 hrs. Finished cores
were suspended on a peg to center in a larger mold that
allowed for a CS mixture to be injected, completely surrounding the CS core.
Drug Loaded Samples
To test the release of a bioactive agent from different CS
layers, 20 mg (2 wt%) of simvastatin was directly mixed
into 1 g of CS and combined with 800 µL DI and used to
produce either the shell only loading (SSBC), core only
loading (BSSC), or both shell and core loading (SSSC). For
samples containing PLGA loaded with 12.5 wt% metron
idazole, the particles were added to both the blank and
simvastatin-loaded shells at either 1 or 10 wt % and then
mixed with 850 µL DI water in 3 mL syringes fitted with a
blunt-tipped needle for easy, consistent filling of the mold.
Bilayered Calcium Sulfate/Calcium Phosphate Composites
To enhance mechanical stability, dicalcium phosphate
dihydrate (DCPD) was added to the bilayered implants
(FIG. lOb). CP slurries were prepared by combining 1 g
DCPD (a mixture of monocalcium phosphate monohydrate
and �-tricalcium phosphate with a 1:1 molar ratio) powder
and 400 µL of 100 mM sodium citrate. Cores with either CS
or DCPD slurries were packed into a mold and kept in either
a 43 ° C. oven or a desiccator under vacuum for 24 hr,
respectively. Finished cores were inserted in a larger mold
that allowed for a slurry mixture to be packed around the
cores. Final samples consisted of CP blanks, CP-shell/CS
core, and CS-shell/CP-core.
The process illustrated in FIG. 10 depends on a variety of
parameters, including but not limited to:
Slurry mixture for calcium sulfate composites is fluid
enough to be injected allowing for consistent easy
filling of the molds.
To suspend the calcium sulfate cores small metallic pegs
were inserted allowing for accurate and consistent
orientation. Pegs were removed before testing.
For calcium sulfate/calcium phosphate implants, prefab
ricated DCPD cores were correctly oriented in the mold
for shell production via a small insert located on the
bottom plate of the mold.
DCPD was packed under pressure into the molds.
Although the compressive properties decreased with the
introduction of a layered geometry, the resulting strengths
for calcium sulfate bilayered composites remained either
similar to or stronger than the strength of trabecular bone in
the mandible. Calcium sulfate/calcium phosphate samples
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were even stronger still. Further, preformed scaffolds can be
designed to allow fabrication of a variety of shapes.
Mechanical testing was measured using a Bose ELF 3300
system and demonstrated the ultimate compressive strength
(UCS) and compressive elastic modulus (M) of the materials
(FIG. 18). These data demonstrate the effect of the bilayered
geometry compared to the single layer samples and trabe
cular bone. Further, microcomputed Tomography (microCT)
demonstrated the structural integration of the layered com
ponents and allowed for analysis of structural changes
during the erosion of the bilayered materials (FIG. 11).
Tests were also performed on the destructive degradation
of the bilayered composites. These data allowed for the
evaluation of the erosion process of the samples. Samples
were weighed and placed in separate plastic vials containing
4 mL of PBS, and all the samples were incubated on a shaker
plate at 37° C. Every 4 days replicate samples were collected
and dried at 43° C. for a minimum of 24 hours. Dried
samples were weighed to determine mass loss. FIG. 19
shows representative data for mass loss and pH. The erosion
pattern of the layered materials has potential for erosion
tuning and customizable drug release that could be useful for
a bone graft substitute.
Example 3
Drug-Loaded Bilayered Calcium Sulfate/Calcium Phos
phate Composites
CS slurries were prepared by mixing 1 gram calcium
sulfate hemihydrate (Sigma-Aldrich) with 800 µL of deionized (DI) water. To test the release of a bioactive agent, 10
mg (1 wt%) of simvastatin was directly mixed into the CS
prior to addition of water. CS blanks were also made without
the addition of simvastatin The CS slurry was then injected
into a cylindrical Teflon mold of average height 6.5 mm and
diameter 4.75 mm and then kept at 43° C. for 24 hrs. Any
trapped air was removed by tapping the mold on a hard
surface as the slurry sets. CS samples were then removed
and stored in a dry environment at room temperature. CS
samples had an average dry weight of 0.10±0.02 g.
Adapting from what was originally proposed by Lemaitre
et al. (Lemaitre, J.; Mirtchi, A. A.; Mortier, A. Calcium
phosphate cements for medical use: State of the art and
perspectives of development. Silic. Ind. 1987, 9-10, 141146), DCPD slurries were prepared by combining a mixture
of MCPM and �-TCP with a 1: 1 molar ratio at 1 gram total
mass with 400 µL of 100 mM sodium citrate as a setting
retardant to form the DCPD. Similar to CS, simvastatin was
added to the 1 gram powder mixture prior to mixing with
citrate at 10, 20 and 50 mg (1 wt%, 2 wt%, and 4.8 wt%,
respectively). Mixing the components after the addition of
sodium citrate-rather than prior-helps to slow the setting
of the mixture. The DCPD slurry was packed firmly into a
cylindrical Teflon mold of height 6.5 mm and diameter 4.75
mm. Any trapped air was removed by tapping the mold on
a hard surface as the slurry sets. The samples were then
allowed to set in a fume hood at room temperature for 24 hrs.
DCPD samples were then removed and stored in a dry
environment at room temperature. DCPD samples had an
average dry weight of 0.17±0.008 g.
In order to prepare CS-shell-DCPD-core (CS/CP)
samples, DCPD slurry was prepared. The slurry can also be
mixed with 2 wt% simvastatin for a drug loaded core (CPs).
The slurry was then packed into a cylindrical Teflon mold of
height 10 mm and diameter 2.35 mm. The cement was then
allowed to set in a fume hood at room temperature for 24 hrs.
The samples were then removed and held in place at the
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center of a wider Teflon mold of height 6.5 mm and diameter
4.75 mm. The samples were held in place using thin molds
of equivalent diameter. CS slurries were then prepared with
some as blanks and some with 1 wt% of simvastatin to form
a simvastatin loaded CS shell (CSs). The slurries were then
injected around the DCPD samples and any trapped air was
removed tapping the mold on a hard surface as the slurry
sets. The samples were kept in a dry environment at 42° C.
as they set. The resulting bilayered samples were carefully
removed from their mold and any DCPD extruding from the
CS was sanded down. Samples were then removed and
stored in a dry environment at room temperature.
For the preparation of DCPD-shell-CS-core (CP/CS)
samples, DCPD slurries were prepared with and without the
addition of 2 wt % simvastatin. The slurry is then packed
into a cylindrical Teflon mold of height 6.5 mm and diameter
4.75 mm with a 10 mm height and 2.35 mm diameter steel
dowel rod held in place in the center with a thin mold of
equivalent diameter. After being packed, the cement was
allowed to set in a fume hood at room temperature for 24 hrs.
The dowel rods were then punched out carefully without
significantly damaging the DCPD shell. CS slurries were
then prepared with and without the addition of 1 wt %
simvastatin. The slurries were then injected at the center of
the DCPD shell. Any trapped air was removed by tapping
the mold on a hard surface as the slurry sets. The samples
were kept in a dry environment at 42° C. as they set. The
resulting bilayered samples were carefully removed from
their mold. Samples were then removed and stored in a dry
environment at room temperature.
Simvastatin Release Study
Release studies were conducted on DCPD samples at
simvastatin loadings of 1, 2, or 4.8 wt% (CP-1, CP-2, and
CP-4.8, respectively). The same was done for CS samples
but only at 1 wt% (CS-1). Blanks of CS and DCPD were
made for comparisons. Studies on release of bilayered
CP/CS and CS/CP samples were conducted with drug load
ings and layering of CS/CPs, CPs/CS, CPs/CSs and CSs/
CPs. DCPD layers were 2 wt% and CS layers with 1 wt%.
All release studies were performed using 4 mL phosphate
buffered saline (PBS), pH 7.4, at 37° C. and on a plate
shaker. At the end of every 4 days, samples were transferred
into new vials with 4 mL of PBS and the supernatant from
the previous vials were analyzed using UV spectroscopy.
Release supernatant was mixed with an equal volume of
reagent alcohol to dissolve any remaining simvastatin. After
filtering at 0.45 µm, absorbance was measured at 240 nm.
Compressive Mechanical Testing
Bilayered and non-layered CS and DCPD samples were
mechanically tested in compression using a BOSE ELF
3300 system. After measuring dimensions, samples were
loaded to failure at a rate of 0.5 N/s. From each sample's
stress-strain curve, compressive elastic modulus [Eel and
ultimate compressive stress [ au1,] were calculated.
Destructive Degradation Testing
A total of 30 unloaded non-layered DCPD samples were
weighed and each sample was immersed in 4 mL of PBS.
These samples were then allowed to dissolve at 37° C. on a
plate shaker. The supernatant was aspirated and the samples
were refilled with PBS at the end of every 4 days. At the end
of every 8 days, 3 samples were collected, allowed to dry,
and then weighed for percent change in mass.
Microcomputed tomography (microCT) was used to
evaluate the internal structure of samples during erosion.
Samples were analyzed with a Scanco Medical µCT-40
scanner. The specimens were evaluated with standard resolution having 250 projections with 1024 samples each.
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Additional parameters were set as follows: 92 µm incre
ments, 01 angle, 70 kVp, 114 µA, 0.5 mm Al filter, and a
voxel size of 12 µm. The resulting images were used to
construct a three dimensional model with a built-in 'bone
trabecular morphology' analytical tool at a lower threshold
of 109. The scans and 3D image were then assessed quali
tatively for obvious changes in the internal structure.
Statistics
Statistical analysis of the results was performed using
either a two-tailed, unpaired t-test or one-way ANOVA. As
appropriate, this was followed with a Tukey-Kramer mul
tiple comparisons post hoc test. Any outliers were deter
mined using Grubbs' test. Differences between groups were
considered to be significant with p-value <0.05.
Simvastatin Release Study
Release of simvastatin from CS samples occurred at a
much higher rate than DCPD samples, as expected from
CS's faster dissolution rate. Within 28 days, CS samples
were fully dissolved through surface erosion. FIG. 12 shows
release profiles for CS and DCPD samples loaded each with
1 wt % simvastatin (CS-1 and CP-1). Release rates were
approximately 247 and 29 µg/day for CS-1 and CP-1,
respectively. Increasing the amount of simvastatin added to
DCPD resulted in a loading-dependent increase in release
rate (i.e., 45 and 105 µg/day for 2 and 4.8 wt % simvastain
loadings, respectively).
FIG. 13 shows the release profiles for CP-1, CP-2 and
CP-4.8 and indicates a less linear cumulative release at
higher loadings. This is especially visible in CP-4.8 release
profile where a large increase in release rate was seen
between 32 and 76 days. During the first 32 days of release
the rate for CP with 10, 20 and 4.8 wt % simvastatin was 22,
29, 47 µg/day, respectively. From days 32 to 72, the release
rate for the three samples increased to 37, 57, and 206
µg/day, respectively. After the 72 days, the release rate for
the three samples dropped to 26, 39, and 72 µg/day, respec
tively. At the end of the 180 study of DCPD release, CP-1,
CP-2, and CP-4.8 released a cumulative amount of
1.21±0.33 mg, 1.82±0.30 mg, and 4.20±0.40 mg, respec
tively,-all of which are significantly different from each
other (p<0.05). Interestingly, CP-2 released a similar amount
in the 180 days compared to the total release of CS
(1.82±0.30 mg and 1.60±0.18 mg, respectively).
At the end of the 120 day period, CS/CPs, CPs/CS,
CPs/CSs, and CSs/CPs released a cumulative amount of
229±57 µg, 401±125 µg, 679±210, 1169±197 µg, respec
tively (FIG. 14). Compared to the cumulative release of
CP-1, CP-2, and CP-4.8 samples at 120 days (862±288 µg,
1388±255 µg, 3319±402 µg), CSs/CPs and CPs/CSs had a
cumulative release comparable (p>0.05) to CP-2 and CP-1,
respectively. Bilayered DCPD and CS samples released
simvastatin at much slower rates compared to their non
layered counterparts at almost all instances. CSs/CPs expe
rienced the greatest average release rate of 7.5 µg/day.
However, the release was not steady (R2=0.755); CSs/CPs
had an average release of 32 µg/day in the first 20 days
which then decreasing to 4.1 µg/day from then on. All other
loadings experienced a much more steady release. CPs/CSs,
CPs/CS, and CS/CPs released simvastatin at an average of
5 µg/day, 3.1 µg/day, and 1.92 µg/day, respectively.
It is important to note that after conducting Grubb's test
for outliers, it was found that CP-1 and CP-4.8 each had one
sample with more than 10 timepoints that were considered
outliers; nevertheless, these outliers remain represented in
FIG. 14. With a sample size of 5 and confidence interval of
95%, G= l.672. A total of 45 data points were collected yet
one CP-1 sample released si gnificantly higher on 33 time-
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points (G>1.672). One CP-4.8 sample also released signifi
cantly higher on 28 data points (G>1.672). Outliers in
release were observed in other samples and categories
however they did not occur as significantly frequent as the
ones mentioned previously. No outliers were found in bilay
ered release samples
Compressive Mechanical Testing
Mechanical testing showed DCPD to all have signifi
cantly (p<0.05) greater ultimate compressive strength and
compressive modulus than did CS (FIG. 15). There were no
significant differences (p>0.05) in the two properties
between DCPD blanks and the simvastatin loaded DCPD
samples tested. The same quality was observed when com
paring blank CS and simvastatin loaded CS.
Additionally the strength and modulus of both bilayered
samples were significantly lower (p<0.01) than those of
DCPD blanks. Interestingly, the compressive mechanical
properties of both bilayered samples were comparable
(p>0.05) to that of CS blanks. There was also no significant
difference found between the compressive mechanical prop
erties of CS/CP bilayering compared to CP/CS bilayering
(modulus-219±140 MPa and 220±68 MPa, respectively;
strength---4.6±1.7 and 6.7±1.6, respectively).
It is important to note that three outliers in modulus were
found and removed from CS-1, CP-1 and CS/CP using
Grubb's test for outliers. Data of one sample was missing for
both CS-1 and CP-1, resulting in a sample size of 9. At a
sample size of 10 and 9 with a confidence interval of 95%,
G=2.176 and 2.11, respectively. It was found that a sample
in CS-1 and CP-1 each had a si gnificantly higher modulus
(G>2.11) compared to its 8 other samples and was removed
accordingly from the data as modulus sample size was
adjusted to 8 for CS-1 and CP-1. One sample in CS/CP was
found to be significantly higher as well for modulus and was
removed according from the data as modulus sample size
was adjusted to 9 for CS/CP.
Destructive Degradation Study
Over a period of 128 days, data was collected on the
percent of remaining mass in samples every 8 days. The data
showed a fairly constant decrease in mass (FIG. 15); how
ever the change in percent remaining mass decreased gradually as the study progressed, suggesting a more logarithmic
relationship. Percent loss in mass was fairly consistent
between samples, indicated by the standard deviation bars.
Between any two consecutive time points, there was no
significant difference in mass loss (p>0.05), however at the
end of the 120 days there accumulated a significant
(p<0.001) mass loss of 36.8±2%. MicroCT scans also
showed qualitatively that DCPD developed a porous internal
structure as it eroded (FIG. 16).
Simvastatin Release Study
As loadings increased in non-layered DCPD samples, a
larger release rate was seen between 32 and 76 days. The
increase was much less obvious in lower loadings, however
it can be clearly seen in 50 wt % loadings. It was observed
that the average daily release suddenly increased in all
DCPD samples between 32 and 76 days before decreasing to
a rate slightly higher than the initial release rate during the
first 32 days. The sudden increase can be due to the
formation of porous structures within the sample which
increase surface area within the sample and proportionally
increase simvastatin release. The subsequent drop in release
can be attributed to the partial transformation of DCPD to
the less soluble calcium deficient hydroxyapatite
(CDHA) C-0.088 g/L vs. -o.0094 g/L at 25° C., respectively)
(Dorozhkin S V, Calcium Orthophosphates in Nature, Biology and Medicine. Materials. 2009; 2(2):399-498) which
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precipitated over time within and as a layer around the
sample, thereby slowing the release of drug.
In a similar in vitro study on the compositional changes
during degradation in �-TCP and MCPM formulations of
DCPD, there were slight CDHA conversions observed in a
period of 14 days (Alge, D. L., Goebel, W. S., Chu, T-M. G.
(2013) Effects of DCPD cement chemistry on degradation
properties and cytocompatibility: comparison of MCPM/�
TCP and MCPM/HA formulations. Biomedical Materials,
8.2, 1-8). Acknowledging that conversions from DCPD to
CDHA require crystal nucleation as the rate-limiting step
(Bohner M et al 2003 Compositional changes of a dicalcium
phosphate dihydrate cement after implantation in sheep.
Biomaterials 24 3463-74), it is likely that slight initial
CDHA conversions provided for nucleation sites for further
CDHA precipitation. Based on observation and results, the
precipitation of CDHA may have occurred both within
DCPD as it dissolved to form its porous matrix and outside
as a layer around the sample. As complex porous structures
formed within the DCPD sample, it became increasingly
more difficult for dissolved calcium and phosphate ions to
leave the sample, leaving a saturated environment within the
DCPD. This in turn would force the precipitation of the ions
as the more stable and less soluble CDHA. The same effect
may have occurred outside the sample due to higher concentrations of calcium and phosphate ions around the sample
due to dissolution at the surface and slight precipitation. This
effect can be seen in the mass loss of non-layered DCPD
samples which slows over a 120 day period despite increasing surface area due to increasing porosity. Thus, there is
evidence to suggest a conversion of DCPD into CDHA
which works to slow dissolution and drug release.
The results from the release study suggest that higher
loadings should be preferred over lower loadings in order to
have a higher average release rate, while lower loadings are
preferred over higher loadings in order to have a steadier
release rate. Of the three loadings tested, CP-2 seems to be
the ideal candidate for a higher release rate while maintaining its steadiness of release. Studies have shown beneficial
effects of 1.2 mg topical application in human trials of
simvastatin for mandibular defects (Pradeep AR, Priyanka
N, Kalra N, Naik S B, Singh S P, Martande S. Clinical
efficacy of subgingivally delivered 1.2-mg simvastatin in the
treatment of individuals with Class II furcation defects: a
randomized controlled clinical trial. J Periodontal. 2012;
83:1472-9; Pradeep A R, Thorat M S. Clinical effect of
subgingivally delivered simvastatin in the treatment of
patients with chronic periodontitis: a randomized clinical
trial. J Periodontal. 2010; 81:214-22; Rao N S, Pradeep AR,
Bajaj P, Kumari M, Naik S B. Simvastatin local drug
delivery in smokers with chronic periodontitis: a randomized controlled clinical trial. Aust Dent J. 2013; 58:156-62).
Knowing the performance of non-layered CS-1 and nonlayered CP-2, behavior of bilayered release of simvastatin
with CS and DCPD layers can be predicted to an extent. Due
to CS's rapid dissolution, CSs-shell layering was predicted
to have a higher release rate in the first 28 days of its
dissolution. This was supported by the release profile of
CSs/CPs in this experiment whose release in the first 20 days
was 780% greater than its release rate after that point.
Additionally, CS-shell samples would result in greater mass
loss since more surface area is exposed to outside conditions, leaving behind the slower degrading DCPD core. This
is beneficial for providing longer-lasting scaffolding for
implantations while also allowing room for sufficient bone
growth as the outer CS layer dissolves.
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While CS dissolves much more rapidly than DCPD, its
degradation can be retarded by surrounding it with the
DCPD shell. In all CS core samples, CS dissolution lasted
longer than the 28 days for CS non-layered samples and
there was not as dramatic of an initial release as that of
CSs/DCPDs samples. This quality is especially important
for improved biocompatibility since the early dissolution of
CS in CS/CP samples is associated with a significant drop in
pH levels (McQuinn, M. (2014, September). Bilayered Cal
cium Phosphate/Calcium Sulfate Bone Graft Substitutes.

Poster presented at the 96'h Annual Scientific Sessions &
Exhibition, Honolulu, Hi.). The release of simvastatin from
DCPDs/CSs samples was much steadier than CSs/DCPDs.
As expected, DCPDs/CS and CS/DCPDs formulations
had a slower yet more linear release rate compared to other
bilayered formulations. DCPDs shells release at a higher rate
by occupying more volume compared to DCPDs cores. The
formation of an empty core as DCPD-shell samples dissolve
can also be beneficial for providing greater mechanical
strength than a DCPD core while also allowing for bone
growth to occur at the center of the shell. This can also help
to promote the resorption of precipitated CDHA by increas
ing surface area.
It is important to note that the release of simvastatin is less
predictable due to the effect of precipitation of CDHA as
DCPD dissolves (Xie, J., Riley, C., Chittur, K. Effect of
albumin on brushite transformation to hydroxyapatite. J.
Biomed. Mater. Res. 2001, 57, 357-365; Ginebra, M. P.;
Canal, C.; Espanol, M.; Pastorino, D.; Montufar, E. B.
Calcium phosphate cements as drug delivery materials. Adv.
Drug Deliv. Rev. 2012, 64, 1090-1110). Additionally, there is
evidence to show that hydroxyapatite may form from CS
formulations as well (Nilsson, M., Wang, J-S., Wielanek, L.,
Tanner, K. E., Lindgren, L. (2004). Biodegradation and
biocompatibility of a calcium sulfate-hydroxyapatite bone
substitute. The Journal ofBone & Joint Surgery (Br), 86-B,
120-125). The formation of the apatite layer results in
slowed release and was observed in this experiment. In two
of the CSs/DCPDs formulations, portions of the CSs outer
layers developed a hard shell that prevented them from fully
dissolving the expected 28 days. This was also observed in
DCPDs/CSs formulations where the dissolution of CSs was
halted by the precipitation of CDHA on both ends of the
cylinder.
Compressive Mechanical Testing
Blank DCPD samples tested in this study had an overall
mean compressive strength that was 219% higher than that
of the blank CS samples (14.27±2.46 MPa vs. 6.52±1.04
MPa). However, there were no significant changes (p>0.05)
found in strength and modulus as loadings increased in CS
and DCPD compared to their respective blanks. The quality
for DCPD and CS to retain its mechanical properties at the
loadings tested in this experiment allows for more options in
controlled drug release which is important for regions of
bone defect where healing is slower and requires increased
drug loadings to compensate.
It is important to note that DCPD samples have mechanical properties much greater than their CS counterparts and
this is seen in FIG. 14. Consequently, the addition of DCPD
to CS in a bilayered formation was expected to effectively
enhance the modulus and strength. However, properties
were similar to those of non-layered CS. Regardless, the
mechanical properties observed in this experiment were
comparable to or exceeded those of trabecular bone in the
mandible (96.2 MPa modulus; 3.9 MPa strength) (Misch C
E, Qu Z, Bidez M W. Mechanical properties of trabecular
bone in the human mandible: Implications for dental implant
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treatment planning and surgical placement. J Oral Maxi!
Surg. 1999; 57:700-6; McQuinn, M. (2014, September).
Bilayered Calcium Phosphate/Calcium Sulfate Bone Graft
Substitutes. Poster presented at the 96'h Annual Scientific
Sessions & Exhibition, Honolulu, Hi.). Furthermore, a
redeeming quality in bilayered samples is that the inclusion
ofDCPD allows for an adequate support structure in implan
tation sites much longer than CS samples due to its slower
dissolution. Additionally, as discussed in the previous sec
tion, simvastatin loaded DCPD/CS layering allow for a
steady and long term release.
Destructive Degradation Study
The DCPD biocements formulated in this experiment
possess beneficial degradation properties for the purposes of
promoting bone augmentation. DCPD forms porous structures as it degrades through bulk degradation. These non
erodible matrices form as DCPD degrades due to continuous
dissolution and precipitation which result in less soluble
CDHA crystals precipitating from the �-TCP, MCPM, and
sodium citrate mixture (Bohner, M. pH variations of a
solution after injecting brushite cements. Key Eng. Mater.
2001, 192-195, 813-816; Alge, D. L., Goebel, W. S., Chu,
T-M. G. (2013) Effects of DCPD cement chemistry on
degradation properties and cytocompatibility: comparison of
MCPM/�-TCP and MCPM/HA formulations. Biomedical
Materials, 8.2, 1-8. http://stacks.iop.org/1748-605X/8/i=2/
a=025010). Contrastingly, CS undergoes surface erosion as
it dissolves. The structure ofDCPD as it degrades can allow
for infiltration ofmesenchymal cells while osteogenic activi
ties are promoted by the local release of simvastatin.
MicroCT scans showed slight surface imperfections in
DCPD samples even before degradation testing began.
These surface imperfections were found to be as wide as 100
µm in diameter which is sufficient for infiltration of osteo
blasts (20-30 µm). A study done by Zerba et al (2005)
confirmed the possibility ofcell infiltration in porous �-TCP
samples through connected micropores as samples under
went dissolution (Zerba, I. R., Brockers, A. L. J. J., Lange,
G., Burger, E. H. (2005) Localization of osteogenic and
osteoclastic cells in porous �-tricalcium phosphate particles
used for human maxillary sinus floor elevation. Biomateri
als, 26.12, 1445-1451).
Another property of the 13-TCP/MCPM formulation of
DCPD is its ability to maintain pH as it degrades compared
to other formulations such as MCPM and hydroxyapatite
which significantly lower pH levels (Alge, D. L., Goebel, W.
S., Chu, T-M. G. (2013) Effects ofDCPD cement chemistry
on degradation properties and cytocompatibility: compari
son of MCPM/�-TCP and MCPM/HA formulations. Bio
medical Materials, 8.2, 1-8). This is an important factor to
sustain biocompatibility of the samples.
A problem with CS is its rapid dissolution which has been
shown in animal trials and can have unfavorable outcomes
(Thomas, M. V., Puleo, D. A., Calcium sulfate: A review. J.
Long Term Eff. Med. Implants, 15(69):599-607, 2005,
29(5):282-288, 2001; Nilsson, M., Wang, J-S., Wielanek, L.,
Tanner, K. E., Lindgren, L. (2004). Biodegradation and
biocompatibility of a calcium sulfate-hydroxyapatite bone
substitute. The Journal ofBone & Joint Surgery (Br), 86-B,
120-125). This is presumably due to the rapid loss of CS
mass and loss in mechanical properties which may not
provide sufficient time or conditions for bone augmentation
to occur. DCPD's much slower degradation rate may rem
edy this issue. In this study, over a period of 120 days,
DCPD samples maintained 63.18±2% of their initial mass
while CS dissolved in 28 days. The much slower degrada
tion rate in DCPD observed is also beneficial for maintain-
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ing a slow consistent release over a sustained period time as
observed in the release study.
For the purposes of effectively promoting bone growth
while maintaining a strong support structure, simvastatin
loaded CP/CS bilayered bioceramics may be an effective
alternative to CS for procedures such as GBR. While CS
proves to be a highly biocompatible and biodegradable
material, its rapid dissolution is a quality that is largely
undesired for larger areas of defect where bone healing
would take longer than the 28 days which CS permits. The
rapid dissolution ofCS leads to the decline in its mechanical
properties and can also generate gaps where bone growth
'lags' behind (Nilsson, M., Wang, J-S., Wielanek, L., Tanner,
K. E., Lindgren, L. (2004). Biodegradation and biocompat
ibility of a calcium sulfate-hydroxyapatite bone substitute.
The Journal ofBone & Joint Surgery (Br), 86-B, 120-125).
Additionally, non-layered DCPD may not be ideal either due
to its much slower degradation rate (>180 days) which will
permit little bone growth as the sample degrades. These
issues can be addressed by combining the two ceramics
using CP/CS bilayered bioceramics by providing a longer
lasting support structure (DCPD) while also permitting
sufficient bone growth to occur within the core as the faster
degrading CS is dissolved. After bone ingrowth has occurred
within the core of the DCPD shell, mechanical properties
can expect to see a boost due to the presence of both bone
and DCPD. Additionally, cell infiltration and resorption can
occur on both sides ofthe DCPD shell, thereby allowing for
better integration of bone and effectively reducing the deg
radation time ofDCPD. Additionally, the osteogenic activity
will be enhanced by the steady and predictable release of
simvastatin from the sample, all without compromising the
initial mechanical strength of the commonly used CS.
CS and DCPD are both proven alternatives to conven
tional bone grafts. DCPD possesses advantages such as
stronger mechanical strength, prolonged release, and inter
nal conditions which promote bone growth. Preferred load
ing amounts in DCPD were determined to be 2 wt %, and
increased loadings up to 4.8 wt % did not affect the mechani
cal strength of the material. Additionally, bilayered CS and
DCPD samples were tested where it was discovered that
CSs/CPs samples released more simvastatin at any period of
its degradation compared with any other layering option,
however CSs/CPs had a much steadier release rate and
higher mechanical strength which is equivalent to that ofCS.
Bilayered CS and DCPD samples may allow for more
options for treatment ofbone defects rather than using solely
CS or DCPD. Ultimately, the use ofone bioceramic over the
other will depend on the desired compressive strength,
degradation, and drug release when confronted with differ
ent sites for bone augmentation. However, CPs/CSs formu
lations seem to be a more interesting candidate for future in
vivo testing and applications.
The foregoing descriptions of various embodiments pro
vide illustration of the inventive concepts. The descriptions
are not intended to be exhaustive or to limit the disclosed
invention to the precise form disclosed. Modifications or
variations are also possible in light of the above teachings.
The embodiments described above were chosen to provide
the best application to thereby enable one of ordinary skill
in the art to utilize the inventions in various embodiments
and with various modifications as are suited to the particular
use contemplated. All such modifications and variations are
within the scope of the invention. All publications, patents
and patent applications referenced herein are to be each
individually considered to be incorporated by reference in
their entirety.
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We claim:
from the group consisting of: simvastatin, lovastatin, rosu
vastatin, bone morphogenetic proteins, human parathyroid
1. A bilayered bone graft composite for bone augmenta
hormone fragment 1-34, metronidazole, doxycycline, van
tion comprising an outer shell layer comprised of a first
comycin, gentamycin, ciprofloxacin, ketoprofen, celecoxib,
bioceramic and an inner core layer comprised of a second
diclofenac, meloxicam or combinations thereof.
bioceramic, wherein the first and second bioceramics are
9. The bilayered composite of claim 8, wherein both
different such that one layer degrades in situ within a subject
layers further comprise a pharmaceutical agent.
at a rate faster than the other layer to allow for cell
10. The bilayered composite of claim 8, wherein the
infiltration in situ with the slower degrading layer preformed
pharmaceutical agent is preloaded in a degradable matrix or
to mechanically support the bilayered bone graft composite
and surrounding tissue in situ and further wherein the inner 10 a hydrogel.
11. The bilayered composite of claim 1, wherein the
core layer is encased by the outer core layer.
subject
is an animal.
2. The bilayered composite of claim 1, wherein the outer
12. The bilayered composite of claim 1, wherein the
shell layer degrades faster than the inner core layer.
subject is a human.
3. The bilayered composite of claim 1, wherein the inner
15
13. The bilayered composite of claim 1, wherein the outer
core layer degrades faster than the outer shell layer.
layer
further comprises polymer particles.
4. The bilayered composite of claim 1, wherein one layer
14. The bilayered composite of claim 1, wherein the inner
c?mp�ises a material selected from the group consisting of
layer further comprises polymer particles.
d1calcmm phosphate dihydrate (DCPD), hydroxyapatite,
15. The bilayered composite of claim 1, wherein the inner
calcium-deficient hydroxyapatite, carbonate-substituted
20
layer
and the outer layer form concentric cylinders.
hydroxyapatite, and calcium polyphosphate.
16. A method of providing tissue support to a subject in
5. The bilayered composite of claim 4, wherein the other
need thereof, comprising administering the bilayered com
layer comprises a material selected from the group consist
posite of claim 1 to tissue of the subject.
ing of calcium sulfate (CS), �-tricalcium phosphate, amor
17. The method of claim 16, further comprising preloadphous calcium phosphate, monetite, and tetracalcium phos
25 ing one layer with a pharmaceutical agent.
phate.
18. The method of claim 17, wherein the pharmaceutical
6. The bilayered composite of claim 1, wherein one layer
agent is in a degradable matrix or hydrogel within the layer.
comprises calcium sulfate and the other layer comprises
19. The method of claim 16, wherein both layers further
calcium phosphate.
comprise preloading with a pharmaceutical agent.
7. The bilayered composite of claim 6, wherein the
30
20. The method of claim 16, wherein the tissue is osseous
calcium phosphate is dicalcium phosphate dihydrate.
tissue.
8. The bilayered composite of claim 1, wherein at least
* * * * *
one layer further comprises a pharmaceutical agent selected

